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Molecular Mechanism of Vitamin D Action and
its Implications in Ovarian Cancer Prevention and Therapy
Feng Jiang
ABSTRACT
1,25-dihydroxyvitamin D3 (1,25VD), the active form of vitamin D (VD),
suppresses the growth of numerous human cancer cell lines by inhibiting cell cycle
progression and inducing cell death. Genes that mediate each of these activities remain
largely unidentified and there are no preclinical data for 1,25VD analogues in ovarian
cancer (OCa). We hypothesize that 1,25VD and its analogues inhibit the development of
OCa. In this study, we demonstrated, (a) 1,25VD causes cell cycle arrest at the G1/S and
G2/M transition and induces apoptosis in OCa cells. (b) We also found that gadd45 is one
of primary target genes for 1,25VD- mediated G2/M arrest. A direct repeat 3 (DR3)
vitamin D response element (VDRE) is identified in the fourth exon of gadd45. This
exonic VDRE forms a complex with the vitamin D receptor (VDR)/retinoid X receptor
(RXR) heterodimer in vitro and mediates the induction of reporter activity by 1,25VD in
vivo. VDR is recruited in a ligand-dependent manner to the exonic enhancer but not to the
gadd45 promoter regions. In OCa cells expressing GADD45 anti-sense cDNA or
GADD45- null mouse embryo fibroblasts, 1,25VD fails to induce G2/M arrest, suggesting
that G2/M arrest induced by 1,25VD is mediated through GADD45. Further study
showed that GADD45 mediates the effect of 1,25VD by decreasing cdc2 kinase activity.
(c) hTERT, the catalytic subunit of telomerase, is identified as a primary target for
viii

1,25VD. 1,25VD decreases telomerase activity and hTERT mRNA expression. The
down-regulation of hTERT mRNA is due to decreased mRNA stability by 1,25VD,
rather than decreased transcription of hTERT through VDRE. Clones stably transfected
with hTERT showed higher telomerase activity and longer telomere length than parental
cells. Moreover, hTERT clones resist 1,25VD-induced apoptosis and growth inhibition.
In contrast to parental cells which do not recover from prolonged treatment with 1,25VD,
hTERT clones re- grew rapidly after 1,25VD withdrawal. (d) We demonstrated that the
1,25VD analogue EB1089 inhibits OCa cells in vitro and OCa xenograft in vivo without
inducing hypercalcemia. We also demonstrated precursors for epithelial OCa express
VDR and human primary ovarian surface epithelial cells respond to 1,25VD. Taken
together, these results strongly suggest that 1,25VD analogues may be effective in the
chemoprevention and chemotherapy of OCa.
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INTRODUCTION

Nuclear receptor superfamily
The nuclear receptor superfamily consists of two classes of genes, nuclear
hormone receptors and orphan receptors, which represent one of the most abundant
classes of transcriptional regulators in animals (Robinson-Rechavi, 2003). It affects a
wide variety of functions, including homeostasis, reproductive development, fatty acid
metabolism and detoxification of foreign substances. The cognate ligands have been
identified for nuclear hormone receptors, but for orphan receptors, the physiologically
relevant ligand(s) remain unkown. The discovery of ligands for orphan receptors and
additional receptors has become a very active research field. It has now been almost 20
years since the isolation of cDNAs encoding the glucocorticoid, estrogen and thyroid
receptors (Hollenberg, 1985; Green, 1986; Weinberger, 1986), which were the first
several receptors identified. Novel signaling pathways controlled by nuclear receptors
have opened up new aspects of nuclear receptors action with respect to homeostasis,
reproduction, development and metabolism in various organisms.
Nuclear receptors form a superfamily of phylogenetically related proteins, with 21
genes in the complete genome of the fly Drosophila melanogaster, 48 in humans and,
unexpectedly, more than 270 genes in the nematode worm Caenorhabditis elegans
(nuclear receptor nomenclature committee,1999).
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Nuclear hormone receptors are a class of molecules that function as both signal
transducers and transcription factors. The hormonal ligands for these receptors are
hydrophobic molecules such as the sex steroids (androgens, estrogens, progesterone),
glucocorticoids, thyroid hormones, mineralocorticoids, 1,25VD and retinoids (all-trans
retinoic acid and 9-cis retinoic acid) etc. Other ligands, such as ecdysone, oxysterols, bile
acids, leukotrienes and prostaglandins have been recently identified and characterized to
have receptors that are structurally related to steroid receptor hormones and appear to act
through similar mechanisms as the steroid receptors. Unlike the water-soluble peptide
hormones and growth factors, which bind to cell surface receptors, the fat-soluble steroid
hormones can pass through the lipid bilayer of the cell membrane and interact with their
cognate receptors in the cell. These lipophilic hormones are potent regulators of
development, cell differentiation, and organ physiology.
Classification of nuclear receptors
The nuclear receptor superfamily can be broadly divided into four classes (class I,
II, III and IV), as proposed by Manglesdorf et al. (1995) based on their dimerization and
DNA-binding properties (Fig. 1).
Class I receptors include the known classical steroid hormone receptors, which
function as ligand-induced homodimers and bind to palindromic response element. Class
I receptors include receptors for steroids such as estrogens (ER), progesterones (PR),
glucocorticoids (GR), mineralocorticoids (MR), and androgens (AR), These molecules
have widespread effects on the development and control of the reproductive system
(Beato, 1995; Cole, 1995; Couse, 1998 and 1999).
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Fig. 1. Structural and functional organization of nuclear receptors.
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Fig. 1. Structural and functional organization of nuclear receptors. The six domains
(A-F) of nuclear receptors comprise regions of conserved function and sequences. All of
nuclear receptors contain a central DNA binding domain (DBD), region C, which is the
most highly conserved domain and includes two zinc finger modules. A ligand binding
domain (LBD, region E) is located in the C-terminal half of the receptor, which contains
activation function 2 (AF-2). Between the DBD and LBD is a hinge region (region D)
that has variable length. In the amino terminus, the variable N-terminal region (A/B)
contains transcriptional activation function 1 (AF-1). Some receptors also contain the F
trail, the function of which is poorly understood.
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Steroid receptors are believed to be synthesized in cytoplasms from single
messenger RNAs (mRNAs). In contrast to other nuclear receptors, unliganded steroid
receptors are associated with a large multi-protein complex of chaperones, including
Hsp90 and the immunophilin Hsp56, which maintain the receptors in an inactive but
conformation. When complexed with Hsp90, through amino acid residues at the
receptor’s C-terminus, steroid receptors are unable to bind DNA (Pratt, 1993).
The ER has two subtypes: ERα and ERβ. Considerable divergence between ERα
and ERβ is apparent in the N-terminus (18 % homology). ERα is the predominant
subtype expressed in the major female organs such as ovary, uterus, vagina, mammary
gland and certain areas of central nervous system especially in the hypothalamus. ERβ
exhibits a more limited expression patterns and is primarily detected in the ovary,
prostate, testis, spleen, lung, hypothalamus and thymus (Couse, 1999; Kuiper, 1997). The
differential distribution of each receptor in a certain tissues may reflect their distinct
receptor functions.
The PR is unique among steroid receptors in that it is composed of two naturally
occurring hormone-binding forms of proteins, A and B. The A isoform is an N-terminally
truncated version of the full- length B isoform. The molecular weights of the human
receptors as deduced from cDNA sequence are 98K and 86K, respectively. The A and B
forms of the progesterone receptor differ in their ability to activate target genes and are
regulated differently in various types of cells (Conneely, 2002).
The glucocorticoid receptor was the first transcription factor to be isolated and
studied in detail (Muller, 1991). There are 3 isoforms of GR, α, β and γ. GRα modulates
the expression of glucocorticoid-responsive genes by binding to a specific glucocorticoid
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response element (GRE) DNA sequence. In contrast, GRβ and GRγ inhibit the effects of
hormone-activated GRα (Bamberger, 1995; Ray, 1996; Rivers, 1999), suggesting that
GRβ and GRγ may be a physiologically and pathophysiologically relevant endogenous
inhibitor of glucocorticoid action and may participate in defining the sensitivity of tissues
to glucocorticoids.
The MR is a 107 kD protein. MR was cloned by Arriza et al. (1987) and plays
important roles in regulation of hydroelectrolytic homeostasis. MR activation by
aldosterone raises renal salt reabsorption by increasing the activity of the epithelial
sodium channel in the distal nephron. Although the distal nephron is recognized as the
major site of action of mineralocorticoids, expression of MR in hippocampus, heart, and
endothelium has suggested extrarenal activity (Le Menuet, 2000).
The AR gene is more than 90 kb long and codes for a 76 kD protein. AR mediates
the biological action of androgens, principally testosterone and 5 alphadihydrotestosterone, that play critical roles in the development and growth of the male
reproductive and nonreproductive systems. AR is found in a variety of tissues and
changes throughout development, aging and malignant transformation (Chang, 1988;
Lubahn, 1988).
Class II receptors heterodimerize with the receptor for 9-cis retinoic acid (RXR)
and characteristically bind to direct repeats. Exclusive of the classical steroid hormones,
this group includes almost all other known ligand-dependent receptors. The list of RXRdimer partners includes receptors for thyroid hormone (TR), vitamin D (VDR), retinoic
acid (RAR), 9-cis retinoic acid (RXR), and ecdysone (EcR). These receptors are
necessary for normal development, differentiation or organ morphogenesis (Kastner,
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1995; Sambrook,1994). Moreover, its heterodimeric partner, RXRs, has been thought to
exert multiple functions via their partner. The detection of an abnormal phenotype may
raise the question as to which of these pathways has been affected.
The class II receptors also include former orphan receptors for which endogeno us
ligands have been recently discovered, such as receptors for polyunsaturated long-chain
fatty acids and their metabolites (peroxisome proliferator-activated receptors, PPARs),
oxysterols (LXRs), bile acids (FXR), xenobiotics (xenobiotic receptor/pregnane X
receptor, SXR/PXR and constitutive androstane receptor, CAR). These receptors have
been “adopted” when they were shown to bind a physiological ligand (Chawla, 2001,
Giguere, 1999, Blumberg B, 1998) and are now in the class II receptor category due to
their ability to form heterodimers with RXR. Many of these “adopted” orphan receptors
function as lipid sensors that respond to cellular lipid levels and elicit gene expression
changes to ultimately protect cells from lipid overload.
Three peroxisome proliferator-activated receptors (PPARs) isoforms have been
characterized: PPARα, β/δ and γ. PPARs play a critical role in lipid and glucose
homeostasis. Lately they have been shown to interfere with different steps of the
inflammatory response by modulating the expression of chemokines, chemokine
receptors and adhesion molecules in endothelial cells, smooth muscle cells,
monocytes/macrophages and T cells (Blanquart, 2003).
LXR are commonly known as cholesterol sensors that respond to elevated
cholesterol concentrations. Oxysterols are natural ligands for LXR. LXR is abundantly
expressed in the liver and other tissues that are associated with lipid metabolism (Peet,
1998). Of particular interests are two xenobiotic receptors, SXR/PXR (human steroid
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xenobiotic receptor/pregnane X receptor) and CAR (constitutive androstane receptor),
which regulate the metabolic cascade of toxic endogenous lipids to protect the body from
foreign chemicals. Whereas CAR mediates the response to phenobarbital- like inducers,
SXR/PXR respond to many prescription drugs, steroids and toxic bile acids. These
receptors seems to increase the clearance of foreign chemicals and provide an important
feedforward loop for the xenosensors to initiate another round of signaling (Chawla,
2001; Xie, 2001).
Collectively, unlike the ‘classical nuclear hormone receptors’ of which ligands
were well known before the receptors were cloned and the role of which was well
established in reproduction and homeostasis via feedback regulation, aformentioned lipid
sensors establish a new role for nuclear receptors in activating feedforward metabolic
cascades that maintain lipid homeostasis by governing the transcription of genes involved
in lipid metabolism, storage, transport and elimination.
Most of the orphan receptors fall into the class III and IV categories. They
represent a diverse and ancient component of the nuclear receptor superfamily, being
found in nearly all animal species examined (Blumberg, 1998). Class III receptors, such
as RXR, bind to direct repeats as homodimers. RXR is involved in the transduction of
retinoid signaling pathway and it is activated in vitro by the vitamin A metabolite 9-cis
retinoic acid but little is known of the natural activators of RXR. Although RXR forms
(α, β, γ) can function as homodimers, they also serve as the dimerization partner of other
nuclear receptors including RAR, TR, VDR, PPARs, LXR, FXR. Thus, as a
heterodimerization partner, RXR is involved in the regulation of multiple cellular
pathways. Heterodimers PPAR-RXR, LXR-RXR, and FXR-RXR are permissive because

8

both heterodimeric partners can bind their cognate ligands and induce transcription.
Ligand binding by RXR has been demonstrated in the context of RAR and TR
heterodimers, suggesting the possibility of permissiveness for RXR-RAR and TR-RXR
heterodimers. Recently, allosteric modification of RXR by liganded VDR has been
demonstrated. RXR acquires the holoreceptor conformation in the absence of its cognate
ligand and gains the ability to recruit coactivators. These results provide evidence for
RXR as a functionally active, nonsilent partner in 1,25VD-mediated RXR-VDRdependent gene expression (Bettoun, 2003).
Class IV receptors typically bind to extended core sites as monomers, such as
RevTRα (EAR1) and NGFI-β which recognize the AGGTCA sequence without
repetition.
Although structurally related to the known receptors, no physiological ligands are
known for these orphan receptors that are more numerous than receptors with known
ligands (Blumberg, 1998). Taken together with the future identification of their definite
ligand, orphan receptors will also provide an opportunity to identify potentially new
functions in physiology.
Domain structure of nuclear receptors
Despite their evolutionary and functional differences, members of the nuclear
receptor superfamily generally share a similar structural organization. Typical nuclear
receptor consists of multiple functionally distinct domains, including domains involved in
DNA or ligand binding, dimerization, and transcriptional activation. Once they have
bound their ligands, dimerized and achieved high-affinity association with specific
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responsive elements in DNA, their transactivation domains function together at the
molecular level, resulting in gene activation (Issa, 1998; Kumar, 1999).
The N-terminus of the nuclear receptor, A/B domain, has ligand- independent
transactivation activity, termed activation function 1 (AF-1). The sequence and length of
the A/B domain are highly variable among receptors (Weinberger, 1985). In addition, this
region is the most frequent site of alternative splicing and secondary start sites, also
contains a variety of kinase recognition sequences. It is thought that A/B domain may be
responsible for the receptor-, species-, and cell type-specific effects, as well as promoter
context-dependent properties of nuclear receptor transactivation.
Nuclear receptors are characterized by a central DNA-binding domain (DBD),
which targets the receptor to specific DNA sequences known as hormone response
elements. DBD, which is the most conserved region among various members of the
superfamily, sets the nuclear receptors apart from other DNA-binding proteins. There are
nine cysteine residues within the DBD that are strictly conserved throughout the
superfamily of receptor proteins. The first eight cysteines in the N-terminus coordinate
two zinc atoms to form the so-called zinc finger DNA-binding motifs that are responsible
for high-affinity interaction with specific DNA sequences in the genomic region of
hormone target genes. The first zinc finger contains the P (proximal)-box region, an alpha
helix that is responsible for high affinity recognition of the “core half site” of the
response element. Located within the second zinc finger, D (distal)-box, an alpha helix,
determines the spacing between half-sites and mediates receptor dimerization. The
second zinc finger contains a six-residue region, referred to as the T-box, which has been
suggested to form a dimerization interface for the interactio n with the RXR DBD.
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Adjacent to the DBD is the D or hinge domain. This region has an poorly defined
function. The D domain appears to allow for conformational changes in the protein
structure following ligand binding. Also, this region may contain nuclear locolization
signals and protein–protein interaction sites.
The C-terminal half of the receptor encompasses the ligand-binding domain
(LBD), which possesses the essential property of hormone recognition and ensures both
specificity and selectivity of the physiologic response. Although this domain is highly
variable among family members, all nuclear receptors share a common structure of 10 to
13 alpha helixes organized around a hydrophobic binding pocket. A ligand-dependent
activation function (AF2) is located at the extreme C-terminus (helix-12). LBD also
contains nuclear localization signals, dimerization motifs interaction surfaces for heat
shock proteins, coregulators and for other transcription factors. The AF-2 domain
provides an interactive surface fo r transcriptional corepressors and coactivators which
links nuclear receptor activity with the preinitiation complexs (PIC).
Nuclear receptors act in three steps: repression, derepression and transcriptional
activation (MacDonald, 2001). Repression is cha racteristic of the apo (unliganded)nuclear receptor, which recruits a corepressor complex that possesses histone deacetylase
activity (HDAC). Derepression occurs following ligand binding, which dissociates this
complex and recruits a first coactivator complex that has histone acetyltransferase (HAT)
activity, resulting in chromatin condensation. In the third step, the HAT complex
dissociates and a second coactivator complex is assembled (TRAP/DRIP/ARC), which is
able to establish an interaction with the basal transcription machinery leading to
transcriptional activation of the target gene.
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Nuclear receptors may or may not contain a final domain at the C-terminus of the
E domain, the F domain. The sequence of the F domain is extremely variable among
different receptors and their function is largely unknown.
Regulation of vitamin D receptor
VD and VDR
VD was discovered nearly a century ago as the nutrient that prevented rickets, a
devastating skeletal disease characterized by undermineralized bones (Brown, 1999). VD
is a lipophilic hormone essential for normal bone structure and to maintain serum calcium
levels. VD acts in concert with parathyroid hormone (PTH) to tightly regulate the
concentration of serum calcium and phosphate, thereby assuring proper skele tal
mineralization. In addition to its classic function in mineral homeostasis, the present
concept of VD had been broadened to that of a hormone involved in a complex system
that regulates proliferation and differentiation of a variety of cell types and tissues
(Sutton, 2003) (Fig. 2).
1,25VD is the biologically active form of VD. In the skin, 7-dehydrocholesterol is
photo converted to pre-VD upon exposure to ultraviolet light, is then isomerized to VD.
Subcequently, VD is metabolized in the liver to 25-hydroxy-VD3 and, primarily in the
kidney, to 1,25VD. The major source of VD is through sunlight (UV-B)- induced
photobiosythesis in the skin instead of food consumption (Sutton, 2003) (Fig. 2).
VD action is mediated through the VDR, a member of class II nuclear receptors.
VD-dependent stabilization of the VDR protein appears to occur in virtually all cell
types. VDR heterodimerizes predominantly with RXR. Although VDR also forms
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Fig. 2. Metabolism and biological response of Vitamin D.
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Fig. 2. Metabolism and biological response of Vitamin D. Bioactive 1,25VD is
generated by sequential hydroxylations of its precursor Vitamin D3 in the liver and
kidney. PTH (parathyroid hormone) stimulates 1a-OHase expression in the kidney and
promotes calcium mobilization from the bone and reabsorption from the kidney. 1,25VD,
in turn, induces calcium absorption in the intestine and calcium release from the skeleton.
The action of 1,25VD is mediated through VDR or non-genomic pathway. The distinct
endocrine and paracrine/autocrine roles of 1,25VD are emphasized. The classic and
nonclassic Vitamin D-responsive tissues are also listed.
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homodimers, these homodimers may not be transcriptionally active (Nishikawa, 1994;
Issa, 1998).
The human VDR (hVDR) gene has been localized to chromosome 12q13-14. The
hVDR cDNA was cloned from a human jejunal poly(A)+ RNA library using avian VDR
cDNA probe. hVDR gene contains 11 exons that span more than 75kb (Miyamoto,
1997). The noncoding 5-prime end of the VDR gene includes exons 1A, 1B, and 1C,
while its translated product is encoded by 8 additional exons (2 to 9). Three mRNA
isoforms are produced as a result of the differential splicing of exons 1B and 1C. A 4.6
kb human transcript, contains a 1281 nuc leotide open reading frame that codes for the
full length VDR protein of 427 amino acids. The hVDR coding sequence is highly
homologous to the avian, amphibian, mouse and rat sequences, particularly in the highly
conserved nine cysteine residues of the DBD. Mammalian forms of VDR protein range in
molecular weight between 52-60 by biochemical analysis, although the calculated
molecular weight deduced from the amino acids sequence is 48.3 kD. The promoter of
hVDR is GC-rich and does not contain an apparent TATA box, but has multiple Sp-1
recognition sites and an array of putative binding sites for transcription factors.
VDR shares structural homology with other nuclear receptors. However, AF1 is
absent in the short A/B region at the N-terminus in VDR since removal of the A/B
domain does not affect ligand binding, DNA binding or transactivation (Fig. 3). Two
highly conserved zinc finger DNA binding motifs constitute the DBD, which also
contains the nuclear localization signal. The D domain or hinge region regulates the
receptor’s flexibility for conformational changes. Most of the natural mutations found in
human VDR are located in the zinc finger region, resulting in defective DNA binding and
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the most severe clinical phenotype of VD resistance (Haussler, 1998). The VDR LBD
contains nine heptad repeats that form hydrophobic surfaces thought to act as
dimerization interfaces.
Coregulators of VDR
In response to VD activation, VDR recruits multiple co-activators, including
members of the p160 SRC family (Gill, 1998) and CBP/p300 family (Castillo, 1999) that
either have or can or recruit histone acetyl transferase activity. These coactivators are
essential for the formation of the initial transcription complex with RNA polymerase II.
Recently, another coactivator complex has been identified as DRIP/TRAP complex
(Rachez, 1999) that has no HAT activity and serves as a mediator between the VDR and
RNA polymerase II complex (Pol II). DRIP/TRAP and SRC/p160 exist as distinct
complexes but act cooperatively, as suggested in recent studies where both complexes
were shown to act during the early stages of kerotinocyte differentiation. In the later
stages of differentiation, DRIP/TRAP levels decrease and SRC/p160 assumes a
predominant role (Oda, 2003). In addition to SRC and DRIP, NcoA-62/ski- interacting
protein (skip) can augment VDR transcriptional activity (Baudino, 1998; MacDonald,
2001). Skip lacks LXXLL motifs, selectively associates with the VDR-RXR through the
LBD, but through a domain that is distinct from the Helix3-Helix5/Helix12 interaction
surface. In contrast to coactivators, corepressors, NCoR (nuclear receptor corepressor)
and SMRT (silencing mediator of retinoid and thyroid hormone receptors) have been
found to associate with ligand unbound VDR, TR and RAR to repress ligand- induced
transactivation functions.
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Recently, Kitagawa et al. (2003) identified a multiprotein complex (WSTF
Including Nucleosome Assembly Complex, WINAC); This is a no vel ATP-dependent
chromatin remodeling complex that directly interacts with VDR through the Williams
syndrome transcription factor (WSTF). WINAC, like other SWI/SNF and
ISWI/complexes, can reorganize the chromatin structure either by opening it to allow
transcription or compacting it to repress gene expression. Manipulation of WSTF
expression levels established that it is essential for VDR activity by either stimulating
transcription from promoters regulated by positive response elements or repressing
transcription from promoters containing negative response elements. Overexpression of
WSTF can restore the impaired recruitment of VDR to VD-regulated promoters in
fibroblasts obtained from Williams syndrome patients. This suggests that WINAC
dysfunction contributes to Williams syndrome. This discovery has shed new light on the
molecular mechanisms by which VDR controls gene expression with unexpected clinical
implications (Belandia, 2003).
Phosphorylation of VDR
Hormone induced phosphorylation has been found in most nuclear receptors and
may be involved in the regulation of receptor function. VDR contains two
phosphorylation sites through which its activity can be modulated. Casein kinase
positively regulates VDR activity while protein kinase C or protein kinase A negatively
regulate it (Hsieh, 1991; Jurutka, 1996). VDR is phosphorylated by PKC at Ser-51 in
vitro and in vivo, resulting in retardation of specific interactions of VDR with VDREs.
Ser-208 is the preferred site phosphorylated by casein kinase II (CKII). Phosphorylation
of Ser-51 or Ser-208 is not essential for VDR function but may reflect kinase specific
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inputs that can be either positive or negative. The functional consequence of
phosphorylation on VDR activity depend on both the cellular context and the signal
transduction pathway or specific kinase involved. VDR phosphorylation represent a
mechanism by which signals from the cell membrane in response to growth factor
stimulation can modulate nuclear hormone receptor function.
VDRE and VDR
VDR forms heterodimers with RXR. Isoforms of the RXR (α,β,γ) serve as
dimeric partners for VDR. In most cases, the VDR/RXR heterodimer binds VD response
elements (VDREs) to mediate the biological activities of VD through transcriptional
activation or repression of target genes containing VDREs in their regulatory sequence.
Almost all VDREs were identified in the promoter region of VD-regulated genes (Issa,
1998).
Although there is considerable variations between natural VDREs, a consensus
DR3 type VDRE can be defined as a direct repeat of two six-base half elements of the
sequence, separated by a spacer of three nucleotides. The VDRE sequence directs the
VDR-RXR heterodimer where RXR binds the 5’ half site and VDR occupies the 3’ half
site (Haussler, 1998). The orientation and spacing of the response elements directs the
polarity of heterodimer binding. The fifth nucleotide position of the 3’ half site is thought
to be necessary for heterodimer binding. Although VDR-RXR complexes that interact
with DR3 VDREs predominate the transcriptional response to 1,25VD, alternative routes
appear to be possible both with respect of dimmer formation and target gene VDRE
structure (direct repeat 6, DR6 and inverted repeat 9, IR9). The RXR dimerization
surfaces on VDR are located in the first zinc finger and in a structural motif designated as
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heptad repeats in the LBD. Asn37 in the P-box of the first zinc finger, Lys91 and Glu92
situated in the T-box COOH terminal of the second zinc finger, and two of the heptad
repeats within the LBD are critical in determining selective association between the VDR
and its protein partner, RXR. Heterodimerization of the ligand-activated VDR with RXR
induces a VDR conformation that is essential for VDR transactivating function (Brown,
1999). VDR homodimers showed binding activity for DR6 type elements in both liganddependent and independent manner, while the functional significance of a VDR
homodimer is yet unclear.
Several negatively regulated VDREs were also identified in some genes such as,
avian and human PTH (Liu, 1996) and protein kinase A (PKA) inhibitor (RowlandGoldsmith, 1999). Interestingly, by changing the two 3’-terminal bases GT of the avian
PTH VDRE to the concensus CA, the VDRE reversed from a negative to a positive
VDRE (Koszewski, 1999).
Nongenomic effect of VD
Most of the biological actions of VD are thought to occur through the nuclear
VDR- mediated expression of target genes. Because these responses require transcription
and translation of target genes, they are typically delayed by at least 30 min. However,
more rapid effects (within seconds to minutes) in response to steroid hormones are also
observed. For example, 1,25VD can stimulate the rapid formation of second messengers
including ceramides, cAMP, inositols, calcium and to activate a variety of protein kinases
such as protein kinase C, protein kinase A, raf, MAPK, and src kinases family
(Gniadecki, 1996; Gniadecki, 1998; Marcinkowska, 1997). Although many in vitro
studies have shown rapid effects by 1,25VD and numerous other steroids, the field is
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hindered by the inablility to identify the putative membrane receptors that trigger these
nongenomic effects. The study in VDR-knock out (VDRKO) mice showed that
nongenomic effects of VD in osteoblasts are abrogated in the absence of nuclear VDR,
suggesting that some nongenomic response require a functional nuclear VDR (Erben,
2002). VDRKO mice are important tools to decipher the molecular requirements of
classical VDR that mediate the genomic and nonegenomic effects of 1,25VD in vivo.
Biological actions of VD
The genomic and nongenomic actions of VD produce a multitude of responses.
VDR has been found in classical VD target organs such as the intestine, bone, kidney,
and the parathyroid glands as well as a host of target tissues not involved in calcium
homeostasis, such as skin, muscle, pancreas, reproductive organs, and hematopoietic,
immune and nervous systems (Berger, 1988; Clemens, 1988). The diversity and the
growing number of VD-regulated genes are a reflection of the pleiotropic effects of
1,25VD on calcium and phosphate homeostasis, bone turnover, and proliferation and
differentiation of a wide variety of cells, including keratinocytes, cancer cells and
immune cells. Therefore the diversity and importance of VDR function goes far beyond
mineral metabolism. Moreover, locally produced 1,25VD may serve as a paracrine
modulator of cell growth and differentiation.
To investigate the functional role of VDR, Yoshizawa et al. (1997) generated
mice deficient in VDR. VDRKO mice are viable and develop normally until the weaning
period irrespective of reduced expression of VD target genes. Perhaps, the higher calcium
content of murine milk, compared to human milk, keeps serum calcium normal, assuring
normal growth of VDR-null mutant mice before weaning. Not surprisingly, after
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weaning, VDRKO mice displayed typical features of hereditary vitamin- D-resistant
rickets (HVDRR), a rare genetic disorder caused by mutations in the VDR genes, with
symptoms such as severe bone formation, hypocalcemia and alopecia. Although uterine
hypoplasia, infertility and early lethality are not pronounced in patients with VDdependent rickets type II, possibly because of therapy with calcium supplements, most
VDR-null mutant mice died within 15 weeks after birth; uterine hypoplasia with impaired
folliculogenesis were observed. Uterine hypoplasia was caused by impaired estrogen
synthesis in the mutant ovaries. However, the uterus of these animals responded normally
to administration of estrogen. Male reproductive organs appeared normal in VDRKO
mice. The fact that VDRKO mouse not only exhibits all features of human rickets, but
also has marked growth retardation after weaning and uterine hypoplasia, implicates a
role for VDR and calcium homeostasis during reproductive development and growth.
Classical target tissues of VD related to calcium homeostatis are the intestines
(calcium and phosphate absorption), kidney (phosphate and calcium reabsorption),
parathyroid glands (suppression of PTH) and bone (osteoclasteogenesis, osteoblasts and
mineralization). Target genes in these organs with prominent VDR in their promoters
are the calcium binding proteins calbindin D9K (intestine), calbindin D28K (kidney and
other tissues), the non-collagenous bone-specific matrix protein osteocalcin and
osteopontin (extracellular matrix protein in bone and other tissues) (Haussler, 1998).
Serum 1,25VD is held constant in the normal state and is strictly regulated in response to
factors controlling calcium homeostasis. 1,25 VD regulates its own metabolism and
biosynthesis by stimulation of 24-hydroxylase activity and inhibition of 1α-hydroxylase
(Sutton, 2003).
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In addition to its role in calcium homeostasis and bone metabolism, 1,25VD
exhibits anti- inflammatory and immunosuppressive properties (Bouillon, 1995; Issa,
1998). 1,25VD interacts with mature monocytes and macrophages, enhancing their
immune function and improving host defense against both bacterial infection and tumor
cell growth. In contrast to the stimulatory effects of the hormone on monocytes and
macrophages, the principal action of 1,25VD in lymphocytes is as an immunosuppressive
agent. It does so by decreasing both the rate of proliferation and the activity of T cells and
B cells. 1,25VD and its analogues may prove beneficial as potential therapeutics in
autoimmune diseases, such as psoriasis, multiple sclerosis, rheumatoid arthritis, diabetes
and in transplantation.
Effect of vitamin D in cancer
Epidemiological data suggest that low VD levels increase the risk and mortality
(Fig. 4) of prostate, breast and colon cancers (Waterhouse, 1976; Devasa, 1999). 1,25VD
modulates cellular proliferation and differentiation of both normal and malignant cells.
1,25VD and its synthetic analogues inhibit carcinogenesis in mouse skin (Chida, 1985;
Webb, 1988), decrease the size of transplanted sarcomas, reduce lung metastasis in mice
(Sato, 1982), suppress the growth of human colonic, prostate and pancreatic cancer
xenografts in vivo (Eisman, 1987; Blutt, 2000; Colston, 1997), increase cell
differentiation and decrease proliferation of leukemia (Dodd, 1983), breast (James, 1994)
and prostate cancer (Blutt, 1997) cells. Studies in cancer cell lines have shown that
1,25VD causes cancer cells to accumulate in the G1 phase of the cell cycle (Blutt, 1997),
in the G2 phase (Eisman, 1989) or undergo apoptosis (Blutt, 2000; Simboli-Campbell,
1996). The list of VD- induced proteins (Segaert, 1998) that pertain to cell growth and
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Fig. 4. Ovarian cancer mortality rates in US, 1970-1994 (Devasa DJ et al. 1999, Atlas
of cancer mortality in the United States. NIH publication No. 99-4564: pp 226-230).
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differentiation is rapidly growing with HoxA10 (homeobox protein causing G1 arrest),
Mad1 (differentiation-related transcriptional repressor), TNFα, insulin- like growth factor
binding proteins 3 and 5, apolipoprotein D, tumor suppressors BRCA1 and E-cadherin.
VDREs of numerous VD-responsive genes have been identified and characterized. Some
VDREs are simple direct repeats while others are complex with often overlapping
multimeric structures. The induction of DNA protein kinase links 1,25VD to DNA repair
and cancer chemoprevention mechanisms.
1,25VD and its synthetic analogues appear to exert their growth- inhibitory effects
via regulation of cell cycle progression. Typically, treatment of cells with 1,25VD causes
cell arrest in the G1 phase, resulting in a decreased number of cells in S phase, and
increase in G0 /G1 . This change is associated with alterations in the expression of cell
cycle regulators. Although a number of genes involved in cell cycle control, apoptosis
and cell differentiation have been identified, the exact mechanisms underlying the growth
regulatory actions of 1,25VD and its analogues have not been completely defined.
In prostate model systems, VD has significant anti- tumor activity in vitro and in
vivo (Blutt, 1997 and 2000; Johnson, 2002). The effect of 1,25VD is associated with an
increase in cell cycle arrest, apoptosis, differentiation and modulation of growth factor
receptors. VD induces G0/G1 arrest and modulates cyclin dependent kinase inhibitors,
p21 and p27. VD induces PARP cleavage, increases bax/bcl-2 ratio, reduces levels of pMAPKs, and p-AKT, induces caspase-dependent MEK cleavage and up-regulation of
MEKK-1, increases annexin V binding, which are markers of the apoptosis pathway
(Johnson, 2002). Microarray studies in prostate cancer cells reveal many biologically
relevant molecular targets of 1,25VD. For example, in LNCaP cells, 1,25VD causes
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growth arrest through the induction of insulin- like growth factor binding protein-3
(IGFBP3). These results provide a starting point for additional investigations to fully
elucidate the mechanism of 1,25VD action in the prostate. 1,25VD can also significantly
increase the efficacy of drug- mediated cytotoxicity. Phase I and II trials of 1,25VD either
alone or in combination with carboplatin, paclitaxel or dexamethasone have been initiated
in patients with prostate cancer. Data from these studies indicate that high-dose 1,25VD
is feasible on an intermittent schedule, and provides proof of the concept that 1,25VD or
its analogs are clinically effective (Johnson, 2002).
1,25VD inhibits the proliferation and induces the differentiation of normal and
leukemic myeloid cells into monocytes (Abe, 1981). 1,25VD regulates numerous genes
such as c-fos, c- myc, IL-1, IL-6, TNFα, p21, p27 and Mad1, a pro-differentiating gene.
These findings suggest that 1,25VD action on leukemic cells involves cell cycle control
and differentiation. The response of hematopoietic cells to 1,25VD treatment depends on
the cell type, differentiation state and dose of 1,25VD used. In most cell types, growth
inhibition and maturation accompany each other. Both antiproliferative and
differentiating effects of 1,25VD suggest a therapeutic role for the drug in hematological
malignancies.
In keratinocytes (Kitano, 1991), colonic adenocarcinoma cell lines (ScaglioneSewell, 2000) and squamous cancer cells (Hager, 2001), 1,25VD also blocks cell cycle
progression in the G1 phase, preceded by the induction of the cyclin-dependent kinase
inhibitors p21 and p27. This induction involves direct activation of p21 promoter through
VDRE, as well as indirect mechanisms involving induction of growth inhibitory cytokine
TGFβ1 (transforming growth factor beta 1) and its type II receptor. In squamous cancer
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cells, increased levels of CDK inhibitors prevent phosphorylation of the retinoblastoma
protein and subsequent release of transcription factors of the E2F family. Therefore,
upregulation of S-phase-related genes, such as the proto-oncogene c- myc, is inhibited.
Non-classical positive VDREs were also demonstrated in the promoter of c- fos and
phospholipase C γ1, that both play a role in growth regulatory pathways. In human
osteoblastic cells, cell cycle arrest at G0-G1 by a VD analogue is accompanied by
hypophosphorylation of Rb followed by strong inhibition of Cdk2 activity (Maenpaa,
2001). These effects also correlated with increased level of p27, decreased level of Cdk2
and cyclin E, but p21 and cyclinD1 were not affected. G2/M arrested by VD or a VD
analogue was also detected in Keratinocytes (Kobayashi, 1998).
1,25VD has also been shown to induce apoptosis in breast (Welsh, 1994), prostate
(Hsieh, 1997), colon (Diaz, 2000) and glioma (Baudet, 1996) cell lines. 1,25VD and its
analogues induce apoptosis in MCF-7 breast cancer cells; induction of apoptosis was
associated with upregulation of p53 and Bax. 1,25VD and its analogues are also capable
of inducing apoptosis in T47-D breast cancer cells, which possess a mutated p53. It
appears that induction of apoptosis is independent of p53 status (Mathiasen, 1999). This
study suggests that sensitivity to 1,25VD- mediated apoptosis may be determined by the
relative expression or subcellular distribution of pro- and anti-apoptotic members of the
bcl-2 family rather than activation of any known caspase (Mathiasen, 1999).
Upregulation of apoptosis-related proteins such as clusterin, cathepsin B and TGFβ has
been reported in MCF-7 cells undergoing apoptosis in response to 1,25VD and its
analogues (James, 1996). In prostate cancer cells, 1,25VD- induced decreases in the
levels of antiapoptotic proteins Bcl-2, Bcl- XL, and Mcl-1, BAG1L, XIAP, cIAP1, and
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cIAP2 (without altering proapoptotic Bax and Bak) in association with increases in
apoptosis (Guzey, 2002). Moreover, induction of apoptosis by 1,25VD was suppressed
by overexpressing Bcl-2, a known blocker of cytochrome c release (Blutt, 2000; Guzey,
2002). At this time the molecular mechanisms by which 1,25VD may induce apoptosis
are not fully understood.
Vitamin D analogue in cancer prevention and therapy
Since the potential use of 1,25VD in the treatment or prevention of cancers is
limited by the tendency of 1,25VD to cause hypercalcemia, recent research has focused
on the development of analogues with less calcemic and/or greater antineoplastic activity
than 1,25VD. Numerous VD analogues have been synthesized and many of them have
modifications in the C-17 side chain of VD.
Among them, Seocalcitol (EB1089) is the analog that has been widely
administrated to patients in Europe in a Phase I trial resulting in stabilization of the
disease in patients with advanced breast and colorectal cancer (Gulliford, 1998). EB1089
contains a conjugated double bond system and is approximately 50 times more potent
than 1,25VD in vitro, while the actions of EB1089 in calcium metabolism in vivo are
markedly reduced. Phase II trials with hepatomas showed reduction in tumor dimensions
in patients with an advanced bulky, solid tumor (Dalhoff, 2003). Their studies suggest
that 1,25VD or its analogue have an effect in the treatment of multiple human cancers.
Either 1,25VD or EB1089 in combination with 9-cis RA act cooperatively to
inhibit growth of breast, prostate, ovarian or small cell lung cancer cells (James, 1995;
Guzey, 1998). 9-cis RA is a metabolite of vitamin A that has potent influences on cell
differentiation, proliferation, homeostasis, and development. 1,25VD acts synergistically
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with dexamethasone to suppress growth of breast, OCa and prostate cell lines (Johnson,
2002; Saunders, 1995). These findings have important implications for the use of
retinoids or dexamethasone with 1,25VD in cancer therapy. 1,25VD treatment enhances
the sensitivity of prostate cancer cells to a number of anti-cancer drugs, such as paclitaxel
(Taxol) and cisplatin (cis-diamminodichloroplatinum), indicating that VD compounds
may be useful if used in combination with conventional chemotherapy (Johnson, 2002).
Vitamin D and ovarian cacer (OCa)
Similar to breast and prostate cancers, OCa mortality and incident rates are lower
in countries within 20 degrees of the equator (Waterhouse, 1976) where there are high
amounts of sunlight. In the US women between the ages of 45-54 living in the North
have 5 times the OCa mortality rate than women living in Southern states (Devasa, 1999;
Waterhouse, 1987). The inverse correlation between sunlight exposure and OCa mortality
indicates that in American women decreased synthesis of 1,25VD may contribute to OCa
initiation and/or progression (Lefkowitz, 1994).
OCa has the worst prognosis and remains the most challenging among
gynecological malignancies, since it is not diagnosed at an early stage and has severely
progressed when diagnosed. Although surgical dissection of tumors and intense
chemotherapy is routinly used to treat OCa, severe drug resistance results in only 20-30%
survival rates. Poor response of advanced OCa to current treatments necessitates the
development of novel therapeutic strategies to fight this deadly disease. In recent years
studies have been initiated to develop synthetic VD analogs as therapeutic agents for a
variety of human cancers including breast, prostate and colon cancers, while the similar
studies in ovary are very limited.
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VDR has been found in both normal and cancerous human ovarian cells by
immunohistochemistry; 83.3% of normal surface epithelium shows weak to moderate
VDR immunoreactivity. Moderate to strong nuclear immunoreactivity for VDR was
detected in almost all ovarian carcinomas tested (Villena-Heinsen, 2002). VDR was also
found in rat ovaries by immunohistochemistry (Johnson, 1996) and in hen ovaries by
ligand-binding assays (Dokoh, 1983), indicating that ovarian cells can respond to VD.
VDR expression in gynecologic neoplasms, including OCa (Ahonen, 2000; Saunders,
1992; Villena-Heinsen, 2002), has also been described, indicating that VD could be an
effective agent in OCa treatment and/or chemoprevention. The presence of VDR was
demonstrated in the ovary and the VD- induced decrease in cell number in CHO and
OVCAR3 was also described. Specifically, Ahonen et al. (2000) showed that a 9-day
treatment of OVCAR3 cells with 100 nM 1,25VD resulted in 73% inhibition of growth.
However, the mechanism of VD action in OCa cells, as well as the potential of 1,25VD
and its analogues in OCa treatment remains unknown.
GADD45 and ovarian cancer
The growth arrest and DNA damage- inducibe (GADD) gene GADD45 codes for
a multifunctional protein (19 kD) that binds numerous proteins and plays a role in cell
cycle progression as well as the maintenance of genomic stability. Both genotoxic (i.e.,
UVR, IR, cisplatin, and adriamycin) and nongenotoxic stresses (i.e., apoptotic and/or
growth- inhibitory cytokines, serum starvation) induce GADD45 activation. GADD45α
(GADD45) belongs to the GADD45 family which also contains GADD45 beta and
gamma. GADD45a is the only member that is induced by p53; the p53 binding site has
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been identified in intron 3 (Hollander, 1993). p53- independent induction of GADD45
may also be achieved depending on the insult.
GADD45 interacts with the products of two other p53-regulated genes, p21 and
PCNA (proliferating cell nuclear antigen) (Vairapandi, 1996; Smith, 1994). PCNA
impedes Gadd45- mediated negative growth control (Vairapandi, 2000). Zhan et al.
(1999) have shown that Gadd45, through its association with cdc2, appears to disrupt
interactions between cdc2 and Cyclin B1 and thus may induce arrest at G2 /M.
GADD45- null mice have increased sensitivity to dimethylbenzanthracene
(DMBA)-induced carcinogenesis (Hollander, 2001). It is worth to note that in Gadd45anull mice, DMBA induces a dramatic increase in female ovarian tumors compared to the
wild type (Hollander, 2001). Therefore, GADD45 may protect the ovary from
carcinogenesis, while the role of GADD45 in OCa is not well defined. Although the
upregulation of GADD45 by 1,25VD has been found in squamous cancer cells (Akutsu,
2001), the mechanism of the upregulation and the role of GADD45 in 1,25VD induced
growth inhibition remain unknown.
Telomerase and ovarian cancer
The ends of chromosomes, the telomeres, are subject to progressive shortening in
normal somatic cells, leading ultimately to irreversible growth arrest. In contrast,
telomeres in all cancer cells are stabilized in length and effectively immortalized by the
enzyme telomerase, which catalyzes the synthesis of telomeric DNA repeats. Telomerase
is a ribonucleoprotein complex that is made up of three components: 1. RNA templatehuman telomerase RNA (hTR) contains a sequence complementary to the telomeric
TTAGGG repeat; Telomeres act as protective caps, stabilizing the chromosomes by
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preventing their degradation and aberrant recombination during cell division.

2. Protein

component -human telomerase associated protein 1- (hTEP1). 3. Catalytic subunit,
known as hTERT, which is a type of reverse transcriptase able to synthesize TTAGGG
repeats from the RNA template. The cellular activity of telomerase is determined by the
presence or absence of hTERT. All human somatic cells constitutively express hTR
(Cech, 2004; Newbold, 2002).
Telomerase is responsible for the replication of chromosome end structures and is
strongly upregulated in most human cancers. RT-PCR analysis revealed that hTR and
TP1 mRNA were expressed in more than 80% of OCa and even in normal ovaries. There
was a significant correlation of telomerase activity with hTERT mRNA expression but
not with TP1 or hTR. Repression of telomerase activity is associated with hTERT
mRNA, but the expression of hTR and TP1 remained unchanged (Park, 1999; Kyo,
1999). The rate- limiting step for telomerase activity seems to be the expression of the
hTERT gene. The precise mechanism of how hTERT is regulated has not been elucidated
yet.
It has been shown that OCa cells containing wild type hTERT readily produce
tumors while cells with dominant negative hTERT failed to form tumor in nude mice.
This studya confirms the hypothesis that inhibition of telomerase will decrease
tumorigenicity of OCa cells in vivo and supports the concept that hTERT is a potential
site for anti-cancer drug design for OCa (White, 2001). The protective effect of
telomerase from apoptosis has been proposed for human fibroblasts and neuron cells
(Ren, 2001; Gorbunova, 2002; Fu, 2000). A study of epidermoid tumor cells indicated
that telomerase inhibition in cells with short telomeres leads to chromosomal damage,
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which in turn triggers apoptotic cell death (Zhang, 1999). These data indicated that
inhibition of telomerase activity is a potential approach for the treatment of human
malignancy. Until now, little is known about the mechanism and significance of
telomerase repression by VD in solid tumors including OCa. We observed growth
inhibition by VD in OCa cells. Consequently, the mechanism and role of telomerase in
VD induced growth inhibition was investigated in OCa cells.
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STUDY OBJECTIVES

We hypothesize that 1,25VD through VDR- mediated gene regulation inhibits the
development of OCa; We further hypothesize that 1,25VD and its synthetic analogues
might be used for OCa prevention and therapy. Based on hypothesis, the study objectives
are: 1. Determine the biological responses of OCa cells to 1,25VD treatment; 2. Examine
molecular mechanism of 1,25VD action by identifying target genes which mediate the
different biological response; 3. Test the antitumor activity of 1,25VD analogues in vitro
and in vivo.
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RESULTS
The work presented here provides evidence that GADD45 and telomerase are
regulated by 1,25VD and defines a mechanism for 1,25VD in OCa cells. Our studies
identify GADD45 and hTERT as important mediators of the tumor-suppressing activity
of 1,25VD in OCa cells. Our study also provides preclinical data indicating the
effectiveness of synthetic 1,25VD analogues in OCa prevention and therapy.
Effect of 1,25VD in OCa cells
1. 1,25VD suppresses OCa cell growth and induces cell cycle arrest at G1/S
and G2/M
To better understand the molecular mechanism of 1,25VD action in OCa cells, we
tested the response of OCa cells to 1,25VD in proliferation assays. Cells were treated
with vehicle (ethanol, ETOH) or 10-7 M 1,25VD for 6 or 9 days and cell growth was
determined by MTT assays. As shown in Figure 5, panel A, OVCAR3 cell growth
decreased in the presence of 10-7 M 1,25VD in a time-dependent manner, confirming the
sensitivity of OVCAR3 to VD (Saunders, 1992). Since cell growth was not significantly
affected by 1,25VD at concentrations of 10-8 M or lower (data not shown), it appears that
there is a threshold to the action of 1,25VD.
To determine the mechanism underlying the 1,25VD- induced growth suppression,
OVCAR3 cells were treated with vehicle or 10-7 M 1,25VD for 9 days and analyzed by

35

A
MTT (OD595 )

1.0
ETOH
VD

0.8
0.6
0.4

*

*
0.2
0.0

0

B

ETOH

Percentage of cells (%)

C

6
9
Days of Treatment
VD

G0/G1
80

20
15

30

70

20

60
50

G2/M

S

*

10
0

1

ETOH VD

*
1

ETOH VD

*

10
5
0

1

ETOH VD

Fig. 5. 1,25VD inhibits OCa cell growth and induces cell cycle arrest at G1/S and
G2/M checkpoints.
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Fig. 5. 1,25VD inhibits OCa cell growth and induces cell cycle arrest at G1/S and
G2/M checkpoints. (A) Suppression of cell growth by 1,25VD. OVCAR3 cells were
plated in 96 wells and treated with 10-7 M 1,25VD (VD) or ethanol (ETOH) as a vehicle.
Cell numbers were determined by the MTT assay. Eight samples were analyzed for each
data point, and the data were reproduced three times, *P<0.01 (versus ETOH treatment).
(B) Induction of cell cycle arrest at G1/S and G2/M checkpoints by 1,25VD. OVCAR3
cells were treated with ETOH or 10-7 M 1,25VD for 9 days. Treated cells were subjected
to flow cytometry analysis. Data were reproduced three times. The cell cycle profile of a
representative experiment is shown. G2/M peak (red color) is indicated by the arrow. (C)
Bar graphs show the average percentages of cells at G0/G1, S and G2/M in OVCAR3
cells treated with 1,25VD or ETOH for 9 days, * P<0.05 (versus ETOH treatment).
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flow cytometry. Figure 5, panel B shows that 1,25VD decreased the percentage of cells
in the S phase, which was accompanied by an accumulation of cells in G0/G1 and G2/M.
This suggests that 1,25VD causes cell cycle arrest at both G1/S and G2/M checkpoints.
The increase in G0/G1 was estimated as 13% while the percentage of cells at G2/M
increased by 8% (Fig. 5C), suggesting that cell cycle arrest at both checkpoints
contributed roughly equally to the growth-suppressing activity of 1,25VD. Contrary to
drugs used in conventional cancer chemotherapy, inhibition of cancer cell growth by
1,25VD is a chronic process, explaining why the effect on the cell cycle is modest and
requires treatment for a longer time.
2. 1,25VD induces apoptosis in OCa cells
To determine whether 1,25VD treatment induces apoptosis in OVCAR3 cells,
OVCAR3 cells were treated with vehicle or 1,25VD for 9 days and fragmented DNA was
detected by the Annexin V apoptosis assay kit. Apoptosis was induced to more than 60%
in OVCAR3 cells after 9 days treatment of 1,25VD, as shown in Figure 6.
3. 1,25VD-treated OVCAR3 cells recover slowly after 1,25VD withdrawal.
To determine whether changes induced by 1,25VD are sustainable, we tested
whether growth inhibition of OVCAR3 cells by 1,25VD can be reversed by removal of
the hormone. OVCAR3 cells are treated with 1,25VD for 9 days, and the n 1,25VD was
removed and cells were plated in 96 well plates with fresh medium. Cells were
subsequently grown for an additional 12 days in the absence of the hormone. Consistent
with studies in prostate cancer cells (Blutt, 2000), Figure 7 demonstrated that
OVCAR3 cells pretreated with 1,25VD recover slowly from the treatment when
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Fig. 7. OCa cells recover slowly after 1,25VD treatment. OVCAR3 cells were
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pretreated with 10 M 1,25VD (VD) or ETOH for 9 days. Recovery of treated cells was
assessed at indicated times after plating pretreated cells in 96 well plates. Cell numbers
were determined with the MTT assay. Eight samples were analyzed for each data point,
and the data were reproduced three times.
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1,25VD is removed from the medium compared with vehicle treatment. The poor
recovery of OVCAR3 cells from 1,25VD treatment further confirmed that extensive
growth inhibition was induced by 1,25VD.
G2/M arrest by 1,25VD in OCa cells is mediated through the induction of
GADD45 via an exonic enhancer
To identify the genes that mediate the inhibitory effects of 1,25VD on cell cycle
progression, a microarray analysis was performed to screen for genes that are
differentially expressed in OCa cells treated with vehicle vs. 10-7 M 1,25VD. OVCAR3
cells treated with 1,25VD showed a significant induction of the 1,25VD-dependent 24hydroxylase gene, a gene is known to be upregulated by 1,25VD. In OVCAR3 cells,
1,25VD regulated genes encoded growth factors/modulators, cytokines, kinases and
transcription factors. Some of them were implicated in cell cycle regulation and apoptosis
(data not shown).
GADD45 is a nuclear protein with well-known roles in G2 control and it has been
shown to be upregulated by 1,25VD in our microarray analysis. In order to explore the
molecular mechanism of 1,25VD- induced G2/M arrest, the regulation of GADD45 was
investigated in OCa cells.
1. GADD45 is a primary and immediate early response gene for 1,25VD in
OCa cells
Among the ma ny differentially expressed genes from the microarray experiment,
GADD45 was one of the genes that were upregulated by 1,25VD (data not shown). Since
GADD45 has a well-established role in cell cycle control (Wang, 1999; Zhan, 1999) in
ovarian tumorigenesis (Hollander, 2001), we used Northern blots to confirm GADD45
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regulation by 1,25VD. Compared to cells treated with vehicle, 10-7 M 1,25VD
significantly increased GADD45 mRNA levels; 10-8 M 1,25VD caused a barely
detectable increase (Fig. 8A), showing that 1,25VD induction of GADD45 mRNA is
dose-dependent. The induction was detectable as early as 2 hours following 1,25VD
treatment with maximum induction detected at 8 hours (Fig. 8B), suggesting that
GADD45 is an immediate early responsive gene for 1,25VD. Treatment for times longer
than 8 hours maintained the induction but did not further enhance it. mRNA levels of
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were not affected by 1,25VD,
showing some specificity for the effect of 1,25VD on GADD45. The stability of
GADD45 mRNA, as measured in the presence of actinomycin D, an inhibitor of RNA
synthesis, was not different between cells treated with vehicle and 1,25VD (Fig. 8C),
suggesting that the regulation of GADD45 by 1,25VD is transcriptional. Although the
fold- induction of GADD45 was decreased (Fig. 8D), it persisted in the presence of an
inhibitor of protein synthesis, cycloheximide. This shows that GADD45 induction by
1,25VD does not require new protein synthesis, thus identifying GADD45 as a primary
1,25VD target gene in OCa cells. This is consistent with the data from squamous
carcinoma cells (Prudencio, 2001; Akutsu, 2001).
2. A novel VDRE in the 3’ untranslated region of GADD45 mRNA mediates
the transcriptional up-regulation of GADD45 by 1,25VD
To define the specific DNA elements that mediate the induction of GADD45 by
1,25VD, the genomic sequence of GADD45 was examined for the presence of putative
VDREs. Based on similarity to the consensus VDRE sequence (Toell, 2000)
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CHX

Fig. 8. 1,25VD increases transcription of GADD45 mRNA in OCa cells. (A) Dosedependent induction of GADD45 mRNA by 1,25VD. Total RNA was isolated from
OVCAR3 cells treated with ETOH or 1,25VD (VD) at indicated dosages for 24 h. 20 µg
RNA was used for Northern blot analysis with radio- labeled GADD45 and GAPDH
probes. (B) Time course of the induction of GADD45 mRNA by 1,25VD. OVCAR3 cells
were treated with ETOH or 10-7 M 1,25VD for the indicated times. Total RNA was
isolated and Northern blot was performed as in panel A. (C) Lack of 1,25VD effect on
GADD45 mRNA stability. OVCAR3 cells were treated with ETOH or 10-7 M 1,25VD for
24 h. The cells were washed and subsequently treated with 5 µg/ml actinomycin D
(ActD) for the indicated times. Northern blot analysis was performed as in panel A. The
signals on the Northern blots were quantified using Scion image Beta 4.02 software. The
GADD45 signal was normalized with the corresponding GAPDH signal and presented in
the graph as percentage of the GADD45 mRNA level at time 0. (D) Effect of
cycloheximide (CHX) on the induction of GADD45 mRNA by 1,25VD. OVCAR3 cells
were exposed to ETOH or 10-7 M 1,25VD for 24 h in the absence or presence of 25 µM
CHX. Northern blot was performed as in panel A. The GADD45 signal was quantified
and normalized with the corresponding GAPDH signal as in panel C and presented in the
bar graph as fold induction.
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and the VDRE sequence of known VD target genes, such as osteopontin (OPN) (Noda,
1990) and osteocalcin (OC) (Morrison, 1989), five putative DR3-type VDREs were
identified (Fig. 9A). Four were in introns, one in exon 4 but none in the 5’ promoter
region.
To test which of the five putative VDREs bind the receptors, gel mobility shift
assays (EMSAs) were performed with recombinant VDR and RXR proteins. As shown
in Figure 9, panel B, our conditions allow the detection of a specific VDR/RXR complex
with the OC VDRE. The complex is up-shifted by an RXR antibody and decreased by
excess cold OC probe (upper panel). Under the same conditions, all putative VDREs
except VDRE-C bound RXR/VDR with an affinity comparable to OC VDRE (Fig. 9B,
lower panel). The binding is specific for the VDR/RXR heterodimer since neither RXR
nor VDR alone formed a detectable complex with the VDRE probes. The VDREs were
displaced from the complexes with an excess amount of cold OC VDRE but were not
affected by the putative VDRE-C that did not bind VDR/RXR (Fig. 9C). This shows that
the binding is specific. The RXR antibody up-shifted the complex while a non-related
antibody did not, confirming the presence of RXR in the complex.
To determine whether VDREs binding the receptors in OVCAR3 cells mediate
the induction of GADD45 by 1,25VD, a reporter gene was constructed with a 2.6 kb
genomic DNA fragment of GADD45 containing all the putative VDREs located
upstream of SV40 promoter and the cDNA of firefly luciferase gene (Fig. 10A). In
OVCAR3 cells transiently transfected with this reporter, 1,25VD induced the luciferase
activity in a dose (Fig. 10B) and time dependent manner (Fig. 10C).
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Fig. 9. Multiple putative VDREs are present in GADD45 genome, which interact
with VDR/RXR in vitro. (A) Schematic representation of the human GADD45 genome
and the position of the putative VDREs. The sequences of consensus DR3, mo use OPN
(mOPN) VDRE, human OC (hOC) VDRE and the five putative GADD45 VDREs are
listed. Hexameric VDRE half sites are shown in bold capital letters. The 3-bp space is
shown in small letters. Deviations from the consensus sequence RGKTSA are underlined.
(B) In vitro interaction of VDR/RXR heterodimer with putative GADD45 VDREs.
EMSAs were performed in the presence of 10-7 M 1,25VD using hOC (upper panel) or
putative GADD45 (lower panel) VDRE probes. Pre- incubation with 2 µg anti- RXRβ
(RXR-Ab) or 100-fold molar excess of cold hOC VDRE (Cold- hOC) was performed for
the super-shift and competition experiments, respectively. (C) Specificity of the
interaction between VDR/RXR heterodimer and the putative GADD45 VDREs. EMSAs
were performed as in panel B. Specificity of the interaction was demonstrated by
competition with 100- fold molar excess of unlabeled hOC VDRE oligos as a specific
competitor and the lack of competition with VDRE-C oligos as nonspecific competitor. 2
µg anti-Flag M2 monoclonal antibody was used as a non-specific antibody control for the
super-shifting with anti-RXR antibody.
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Fig. 10. 1,25VD induces GADD45 reporter activity through endogenous receptors
in OCa cells. (A) Schematic representation of GADDLuc construct. (B) Dose-dependent
induction of GADD45 VDRE reporter activity by 1,25VD. OVCAR3 cells were
transfected with 0.2 µg GADDLuc, 0.05 µg pCMVgal, 0.05 µg p91023B-VDR and 0.05
µg pCMX-RXRβ and treated with ETOH or 1,25VD at the indicated concentrations.
Luciferase activity was determined and normalized with cognate β-gal activity. Each data
point was analyzed in duplicate and reproduced three times. (C) Time-dependent
induction of GADDLuc luciferase activity by 1,25VD. OVCAR3 cells were transfected
as in panel A and treated with ETOH or 10-7 M 1,25VD for the indicated times.
Luciferase activity was determined as in panel B. (D) Induction of reporter activity by
1,25VD in cells stably transfected with the GADDLuc. OVCAR3 cells stably transfected
with GADD45 reporter were transfected with 0.05 µg pCMVgal, 0.05 µg p91023B-VDR
and 0.05 µg pCMX-RXRβ and treated with ETOH or 10-7 M 1,25VD for 36 h. Luciferase
activity from two stable clones was determined and shown as fold induction. (E)
Endogenous VDR/RXR in OVCAR3 cells is sufficient for 1,25VD induction of
GADD45 reporter. OVCAR3 cells were transfected with GADDLuc and pCMVgal with
or without p91023B-VDR (VDR) and pCMX-RXRβ (RXR). The total amount of plasmid
DNA was balanced with empty vectors. Luciferase activity was determined as in panel B.
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This induction was also detected in OVCAR3 cells in which the reporter was stably
integrated into the genome (Fig. 10D), showing that it is not an artifact of the transient
transfection. Expression of additional VDR, RXR or both did not further increase the
induction in OVCAR3 cells (Fig. 10E), suggesting that endogenous RXR and VDR in
OVCAR3 cells are sufficient.
To test whether 1,25VD regulates the GADD45 reporter through VDR, the
activation of the reporter was tested in HeLa cells that lack functional VDR. As shown in
Figure 11, panel A, 1,25VD did not induce the activity of a known VDR reporter, p23,
that was constructed with the promoter of 24-hydroxylase (Arbour, 1998). The induction
of the p23 reporter was restored by the ectopic expression of VDR in HeLa cells. Similar
to the p23 reporter, 1,25VD did not cause measurable induction of luciferase activity in
the GADD45 reporter in HeLa cells (Fig. 11B). Co-transfection with VDR restored the
1,25VD induction in a manner that is dependent on the dose of the transfected receptor
(Fig. 11B). Transfection with RXR alone did not affect reporter activity but its cotransfection with VDR enhanced the induction compared to cells transfected with VDR
alone. Similar to the results with OVCAR3 cells, 1,25VD induced reporter activity in
HeLa cells in a dose and time dependent manner after receptor transfection (data not
shown). These experiments demonstrate that the regulation of the reporter is VDRdependent and involves the RXR.
To determine which of the putative VDREs is functional, OVCAR3 cells were
transfected with reporter constructs where VDREs, either individually or in

51

RLU x 10-5

A

10
8
6
4
2
0

ETOH
VD

VDR

B

-

+

10
ETOH
VD

RLU x 10-6

8
6
4
2
0
VDR (ng)
RXR (ng)

-

4
-

40
-

4

40

4
4

40
40

Fig. 11. Induction of GADD45 reporter activity by 1,25VD is VDR-dependent. (A)
The lack of functional VDR in Hela cells. Cells were transfected with 0.2 ?µ g p23 and
pCMVgal with or without p91023B-VDR. Transfected cells were treated and luciferase
activity was determined as in Fig. 10B. (B) VDR-dependent induction of GADD45
reporter activity by 1,25VD. Hela cells were transfected with GADDLuc and pCMVgal
with the indicated amounts of p91023B-VDR, pCMX-RXRβ or both. The total amount of
plasmid DNA was balanced with empty vectors. Luciferase activity was determined as in
Fig. 10B.
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combination, were deleted or mutated by altering key nucleotides known to be essential
for receptor interaction. As shown in Figure 12, panel A, deletion of the VDRE-A or
VDRE-A plus VDRE-B region did not affect 1,25VD induction. Deletion into the
VDRE-D region caused a significant decrease while further deletion into the VDRE- E
region eliminated 1,25VD induction. These analyses suggest that regions around VDRED and VDRE-E are essential for 1,25VD regulation of GADD45.
Site-directed mutation in VDRE-E eliminated the induction, while single or
multiple mutations of key nucleotides in the intronic VDREs had no effect. This suggests
that only VDRE-E is essential for the induction. This conclusion is consistent with the
lack of VD induction in mutant reporters containing only VDRE-D or both VDRE-A and
VDRE-B (Fig. 12A). It is also consistent with the induction of the reporter that contains
only VDRE-E (Luc3) and with the loss of this induction by site-directed mutation of
VDRE-E (MTELuc3) (Fig. 12A).
Individual mutation of the first two VDREs or combined mutation of all first three
VDREs actually increased VD induction, indicating that some VDREs may function in a
negative fashion. The deletion of the VDRE-D region, not the mutation of the VDRE-D
sequence, caused a decrease in VD induction suggesting that DNA elements in the
VDRE-D region for transcription factors other than VDR may cooperate with VDR/RXR
binding to VDRE-E to mediate the up-regulation of GADD45. The lack of a VD effect on
the activity of pGL3-basic, pGL3-promoter and the pGL3-control vectors showed that the
regulation of the reporters by 1,25VD is specific to the GADD45 sequence.

53

A
Wild Type (WT)

Mutant (MT)

Putative VDRE

Putative VDRE

A

B

D

Luc
749
1718
2486

2489

366
366
366
366
366
749
1718
2486

GADDLuc

Luc

Luc1

Luc

Luc2

Luc

Luc3

Luc
1723
1718

Enhancer

E

366

366

SV40

SV40
promoter

E TO
O HH
VD

promoter

Luc

Luc4

Luc

Luc5

Luc

MTALuc

Luc

MTBLuc

Luc

MTDLuc

Luc

MTELuc

Luc

MTABDLuc

Luc

MTELuc1

Luc

MTELuc2

Luc

MTELuc3

Luc

basic

Luc

control
0

2

4

6

8

10

12

14

16

RLU x 10-6

B

-

+

-

+

-

+

VD
Promoter - 1

Promoter - 2

VDRE-E
Mock Input

Rat IgG

VDR

Fig. 12. The VDRE in the fourth exon of GADD45 genome is the functional VDRE
that mediates the transcriptional induction of GADD45 by 1,25VD in OCa cells.

54

Fig. 12. The VDRE in the fourth exon of GADD45 genome is the functional VDRE
that mediates the transcriptional induction of GADD45 by 1,25VD in OCa cells. (A)
Mutational analysis of the GADD45 reporter. OVCAR3 cells were transfected with 0.2
µg of the reporter constructs together with pCMVgal, p91023B-VDR and pCMX-RXRβ
and treated with ETOH or 10-7 M 1,25VD for 36 h. Luciferase activity was determined as
in Fig. 10B and shown on the right. Schematic representation of the different reporter
constructs is shown on the left. pGL3-basic, pGL3-promoter and pGL3-control vectors
were used as controls. (B) ChIP assays. Soluble chromatin was prepared from OVCAR3
cells treated with ETOH or 10-7 M 1,25VD for 60 min. ChIP assays were performed with
control (rat IgG) or anti-VDR antibody. The mock control is performed with
immunoprecipitates from buffer that contains no soluble chromatin from OVCAR3 cells.
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To demonstrate that the VDRE-E interacts with VDR in vivo, OVCAR3 cells
were treated with or without 1,25VD and ChIP assays were performed with anti- VDR
antibodies (Fig. 12B). From soluble chromatin prepared from OVCAR3 cells treated with
1,25VD, the anti- VDR antibody precipitated GADD45 DNA fragments containing the
VDRE-E but not the promoter regions. The specificity of the ChIP assay was
demonstrated by the lack of VDRE-E DNA in the mock as well as in the
immunoprecipitates of rat IgG control. The data shows that VDR is recruited to the
VDRE-E in vivo. More importantly, the recruitment of VDR to the response element is
apparently ligand-dependent since the anti-VDR antibody did not precipitate GADD45
DNA fragments from soluble chromatin prepared from cells treated with the vehicle.
3. Upregulation of GADD45 protein is required for the hormone -induced
cell cycle arrest at the G2/M but not the G1/S checkpoint
Our studies have established GADD45 as one of the immediate early response
genes for 1,25VD, but questions remain whether regulation at the RNA level extends to
the protein level and whether GADD45 mediates the growth-suppressing activity of
1,25VD in OCa cells. To address these questions, OVCAR3 cells were treated with
1,25VD for up to 6 days and GADD45 protein expression was examined by
immunoblotting. As shown in Figure 13, panel A, 1,25VD increased the level of
GADD45 protein in a time dependent manner in OVCAR3 cells whereas the level of βactin remained constant during treatment. Compared to the data on GADD45 mRNA
(Fig. 8B), 1,25VD- induced accumulation of GADD45 protein is a much slower process.
This suggests the presence of additional regulations for GADD45 expression at post-
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transcriptional steps. The slower accumulation of GADD45 protein in response to
1,25VD may explain why the hormonal effect on the cell cycle requires longer treatment.
To test whether GADD45 mediates the inhibitory effect of 1,25VD on OCa cell
cycle progression, OVCAR3 cells were stably transfected with an expression vector
containing GADD45 cDNA in the anti-sense orientation (Zhan, 1994) or an empty
vector. Immunoblot analysis of GADD45 was used to select stable clones with
significantly reduced level of GADD45 protein by the anti-sense GADD45 as compared
to the control clones (Fig. 13B). Although the anti-sense GADD45 did not completely
eliminate GADD45 protein (Fig. 13B), it decreased the expression of GADD45 protein in
the presence of 1,25VD to a level lower than basal level of control clones (Fig. 13B). In
other words, the anti-sense clones represent a functional “knock out” of GADD45 in
terms of VD induction.
Flow cytometry showed that a decrease of GADD45 protein in the anti-sense
clones was associated with an increase of the proportion of cells in G2/M phase and a
decrease of those in S phase (Figs. 13C and 13D). In the control clones, 1,25VD
decreased the percentage of cells in S phase and increased the cells in G0/G1 and G2/M,
showing that the hormone induced a similar cell cycle arrest at both G1/S and G2/M
transitions similar to that in the parental OVCAR3 cells (Figs.5B and 5C). In the antisense clones, 1,25VD-induced G2/M accumulation was blocked whereas 1,25VDinduced decrease in S phase and increase in G0/G1 still occurred (Figs. 13C and 13D).
The data strongly suggest that GADD45 mediates the
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Fig. 13. Anti-sense GADD45 blocks 1,25VD-induced cell cycle arrest at G2/M, but
not G1/S checkpoint. (A) Induction of GADD45 protein expression by 1,25VD in VDsensitive human ovarian cancer cells. OVCAR3 cells were treated with ETOH or 10-7 M
1,25VD for indicated times and the level of GADD45 protein was analyzed by
immunoblotting. Hela cells transfected with pCMV45 plasmid was included as a positive
control. β-Actin was used to show the equal amount of total protein is present in each
lane. (B) Suppression of GADD45 protein expression by stable expression of GADD45
anti-sense cDNA. OVCAR3 cells stably transfected with control vector (VectorOVCAR3) or the anti-sense cDNA of GADD45 (AS45-OVCAR3) were treated with
ETOH or 10-7 M 1,25VD for 24 h. The level of GADD45 and β-actin protein was
determined as (A). (C) Abrogation of 1,25VD- induced G2/M arrest in AS45-OVCAR3
clones. Vector-OVCAR3 and AS45-OVCAR3 clones were treated with ETOH or 10-7 M
1,25VD for 9 days. Cell cycle distribution was determined by flow cytometry. Three
independent experiments were performed and the profile of a representative experiment
is shown. G2/M peak is indicated by arrow. (D) Bar graphs show percentage of cells at
G2/M, G0/G1, and S phases. Each data point was analyzed in duplicate, *P<0.05;
#P>0.05 (versus ETOH treatment).
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inhibitory effect of 1,25VD on the G2/M transition in OVCAR3 cells. Similar to the data
in colon cancer cells (Wang, 1999), the two untreated anti-sense GADD45 clones had
slightly increased G0/G1 and G2/M fractions and slightly lower S fractions, compared
with vector-control OVCAR3 cells.
To firmly establish GADD45 as the mediator for the 1,25VD- induced cell cycle
arrest at the G2/M transition, we tested the effect of 1,25VD on the cell cycle progression
of mouse embryo fibroblasts (MEFs) established from either wild type or GADD45-null
mice (Hollander, 1999). Both MEFs expressed similar levels of VDR protein as
determined on immunoblots (Fig. 14A). It is known that the MEFs from this strain of
mice are a mixture of diploid and tetraploid cells (Hollander, 1999). This complicates the
flow cytometry analysis of diploid cells, largely due to the inability to distinguish diploid
cells at G2/M from tetraploid cells at G0/G1 phases. Therefore, we compared the changes
induced by 1,25VD in the cell cycle distribution of tetraploid cells. As shown in Figure
14, panels B and C, 1,25VD induced a consistent increase in the percentage of cells in
G2/M and a decrease of that in S phase of wild type MEFs, although the magnitude of the
response was less than in OVCAR3 cells. In GADD45-null MEFs, no induction of G2/M
arrest by 1,25VD was observed, confirming the conclusion reached in OVCAR3 cells
with the anti-sense approach that GADD45 is required for 1,25VD- induced cell cycle
arrest at the G2/M transition. In the wild type and GADD45-null MEFs, 1,25VD did not
induce G1/S arrest (data not shown). Since G1/S arrest by 1,25VD was observed in the
MEFs derived from another strain of mice (unpublished data for a separate
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Fig. 14. 1,25VD induces G2/M arrest in wild type but not in GADD45-null MEFs.
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Fig. 14. 1,25VD induces G2/M arrest in wild type but not in GADD45-null MEFs.
(A) Expression of VDR protein in wild type (WT) and GADD45-null MEFs. The level of
VDR protein was determined by immunoblotting with anti- VDR antibody and equal
loading was shown by immunoblotting with anti-β-actin antibody. (B) Induction of G2/M
arrest in WT but not GADD45- null MEFs by 1,25VD. WT and GADD45- null MEFs
were treated with ETOH or 10-7 M 1,25VD for 9 days. The cells were subjected to flow
cytometry analysis. Three independent experiments were performed and the profile of a
representative experiment is shown. The G2/M peak for tetraploid cells is indicated by
the arrow. (C) Bar graph show the percentage of tetraploid cells at G2/M. Each data point
was analyzed in duplicate, *P<0.01 (versus ETOH treatment).
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Fig. 15. 1,25VD decreases cdc2 kinase activity in OVCAR3 transfected with control
vector but not in cells stably transfected with the anti-sense cDNA of GADD45.
Vector-OVCAR3 and AS45-OVCAR3 cells were treated with ETOH or 10-7 M 1,25VD
(VD) for 9 days. Cellular extracts were immunoprecipitated with anti-cyclin B1 antibody.
The activity of cdc2 was assayed using Histone H1 as a substrate. The level of cdc2 and
cyclin B1 protein was determined by immunoblotting. β-Actin blot was included to show
the equal loading.
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study in our lab), the response to 1,25VD appears to vary among MEFs from different
strains.
4. GADD45 mediates 1,25VD-induced decrease in cdc2 kinase activity in
OCa cells
It is well established that the G2/M transition of mammalian cells is controlled by
the M phase promoting factor, a heterodimeric complex between cdc2 and cyclin B.
Studies in recent years suggest that GADD45 may directly regulate the activation of cdc2
kinase (Zhan, 1999). Therefore, the effect of 1,25VD on cdc2 kinase activity in control
and GADD45 anti-sense clones was measured by in vitro immunocomplex kinase assays.
As shown in Figure 15, 1,25VD decreased the kinase activity of cdc2 in the control clone.
In the GADD45 anti-sense clones, there is an increase in cdc2 kinase activity (Fig. 15),
presumably due to the decrease in the level of GADD45 protein. More importantly,
1,25VD did not decrease the activity to a level below the basal activity of control clones.
Immunoblot analysis showed that 1,25VD decreased the level of cyclin B protein and that
the decrease was not observed in the anti-sense clones (Fig. 15), suggesting that
GADD45 mediates the VD effect on cdc2 activity by regulating the cyclin B level in OCa
cells. The data clearly suggest that G2/M arrest induced by 1,25VD in OCa cells is
mediated through GADD45 and the subsequent decrease in cdc2 kinase activity.
Collectively, our data demonstrated that G2/M arrest by 1,25VD in OCa was
mediated through the induction of GADD45 via an exonic enhancer. Next, to further
demonstrate the mechanism of 1,25VD induced growth inhibition, we investigated the
regulation of telomerase by 1,25VD.
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1,25VD-induced apoptosis is mediated by destabilization of hTERT mRNA
and a decrease in telomerase activity
Telomerase activity is increased in most human cancers. It has been shown that
1,25VD reduced telomerase activity in HL-60 human acute myeloblastic leukemia cells
correlated with 1,25VD-induced differentiation (Xu, 1996). In an effort to understand the
mechanism underlying 1,25VD induced apoptosis, our study provides evidence that
telomerase is decreased by 1,25VD and its decrease is responsible for the apoptosis
induced by 1,25VD.
1. 1,25VD down-regulates telomerase activity in OCa cells
Cells undergoing apoptosis are associated with the decrease in telomerase activity
(Saretzki, 2003). As shown in Figure 6, apoptosis was induced more than 3- fold in
OVCAR3 cells by 1.25VD. To fully understand the role of 1,25VD in OCa cells and
determine telomerase function in 1,25VD- induced apoptosis, telomerase activity was
determined in OVCAR3 cells using PCR-based telomeric repeat amplification protocol
(PCR-TRAP) assay. OVCAR3 cells constitutively expressed significant telomerase
activity and 1,25VD decreased telomerase activity in a time-dependent manner (Fig. 16).
PCR-TRAP assay performed with various ammounts of protein indicated that 200 ng of
protein extract provided a quantitative and reproducible assay for telomerase activity on
OVCAR3 cells (data not shown). The activity was not detectable when the extract was
heated to 65o C to abolish the enzymatic activity of protein components of telomerase.
These results confirmed the specificity of the telomerase signal measured in this assay.
Within 3 days of 1,25VD treatment, telomerase activity remained ~ 50% of the control,
whereas at day 6 and day 9

65

1.2
Telomerase Activity
OD450 x 10

1.0
0.8
0.6
0.4
0.2
0.0
-

0

1
3
6
9
Days of treatment

Fig. 16. 1,25VD down-regulates telomerase activity in OCa cells. The OVCAR3 cells
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were treated with 10 M 1,25VD for the indicated times. The protein was extracted and
subjected to the PCR-TRAP assay, as described in Materials and Methods
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Fig. 17. 1,25VD down-regulates hTERT mRNA expression in OCa cells.
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Fig. 17. 1,25VD down-regulates hTERT mRNA expression in OCa cells. Dosedependent inhibition of hTERT mRNA by 1,25VD. Total RNA was isolated from
-7

OVCAR3 cells treated with ETOH or 10 M 1,25VD for indicated times. 2 µg RNA was
used for RT-PCR analysis (A) and Real-time PCR analysis (B) as described in Materials
and Methods. (C) Effect of cycloheximide (CHX) on the inhibition of hTERT mRNA by
-7

1,25VD. OVCAR3 cells were exposed to ETOH or 10 M 1,25VD for 6 days in the
absence or presence of CHX at the indicated concentrations. RT-PCR was performed as
shown on panel A. RNA purified from pBABhTERT transfected OVCAR3 cells as
positive control. RT reaction without reverse transcriptase was the negative control.
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telomerase activity fell to only 15% of the control cell. Combined with data in Figure 5,
these experiments showed that inhibition of telomerase activity by 1,25VD was
correlated with the growth inhibition and apoptosis induced by 1,25VD. These data
supported that 1,25VD induced apoptosis was associated with decreased telomerase
activity.
2. hTERT is a VD-targeted gene in OCa cells
To investigate the mechanism of VD action on telomerase, RT-PCR was used to
determine the mRNA level of hTERT. Compared to cells treated with vehicle, 10-7 M
1,25VD decreased mRNA levels of hTERT in a time-dependent manner (Fig. 17A).
Consistent with decreased telomerase activity by 1,25VD, inhibition began after 1 day of
1,25VD treatment, with further decrease detected after treatment for 3 , 6 and 9 days (Fig.
17A). The mRNA levels of GAPDH were not affected by 1,25VD, showing some
specificity for 1,25VD. In order to quantitatively determine the decrease of hTERT
mRNA, real-time PCR was performed using total RNA purified from OVCAR3 cells
treated with vehicle or 10-7 M 1,25VD. The results confirmed the decrease of hTERT
mRNA after 3 days of 1,25VD treatment and further decrease after 9 days of treatment
(Fig. 17B). These data indicate that the mechanism of telomerase down-regulation
involves the change in the mRNA of hTERT. The down-regulation of hTERT mRNA by
1,25VD persisted in the presence of cycloheximide, an inhibitor of protein synthesis (Fig.
17C), suggesting that hTERT inhibition by 1,25VD does not require new protein
synthesis, and that hTERT is a primary responsive gene for 1,25VD in OCa cells.
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Fig. 18. Putative hTERT VDRE specifically binds to VDR/RXR heterodimer.
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EMSAs were performed in the presence of 10 M 1,25VD using putative hTERT VDRE
probes. Pre- incubation with 2 µg anti- RXRb (RXR-Ab) or 100-fold molar excess of cold
hOC VDRE (Cold- hOC) was performed for the super-shift and competition experiments,
respectively. Specificity of the interaction was demo nstrated by competition with 100fold molar excess of unlabeled hOC VDRE oligos as a specific competitor and the lack of
competition with Gadd45 VDRE-C oligos as nonspecific competitor. 2 µg anti-Flag M2
monoclonal antibody was used as a non-specific antibody control for the super-shifting
with anti-RXR antibody.
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Fig. 19. The putative VDRE is not a functional VDRE in OVCAR3 cells. The
OVCAR3 cells were transfected with 0.2 µg pGL3-3328Luc (A, B) together with 0.1 µg
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CMVbgal and 0.1 µg VDR. The trans fected cells were treated with 10 M 1,25VD, 10

M 9-cis RA or ETOH as indicated. Luciferase activity was determined and normalized by
bgal activity. (C) 3328Luc was stably transfected into OVCAR3 cells. The 3328Luc-7

OVCAR3 cells was treated with 10 M 1,25VD for 6 days and luciferase activity was
determined. (D) ChIP assays. Soluble chromatin was prepared from OVCAR3 cells
-7

treated with ETOH or 10 M 1,25VD for 60 min. ChIP assays were performed with
control (rat IgG) or anti-VDR antibody.
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One putative DR3-type VDRE was identified in the hTERT promoter in a recent
report (Ikeda, 2003). To determine if this putative VDRE is functional in 1,25VDmediated inhibition of telomerase activity in OCa cells, EMSAs were performed and the
results showed that this VDRE bound recombinant VDR and RXR proteins (Fig. 18). The
binding is specific for the VDR/RXR heterodimer since neither VDR nor RXR alone
formed a detectable complex with the VDRE probes. The VDRE was displaced from the
complexes with an excess amount of cold hOC VDRE but was not affected by the nonspecific sequence VDRE-C. VDRE-C has been shown not to bind VDR/RXR in our
previous study (Fig. 9B).
To determine whether binding the receptors to VDRE in vitro mediates the downregulation of hTERT by 1,25VD in OVCAR3 cells, a reporter gene with a 3.3 kb
promoter region of hTERT containing the putative VDRE located upstream of the cDNA
of firefly luciferase gene was analyzed. In OVCAR3 cells transiently transfected with this
reporter, 1,25VD did not decrease the luciferase activity (Fig. 19A). This is consistent
with the study in prostate cancer cells showing that this VDRE- mediated inhibition of
telomerase activity required 1,25VD and 9-cis RA, not 1,25VD alone (Ikeda, 2003).
However, in OVCAR3 cells the combination of 1,25VD and 9-cis RA did not decrease
the activity of telomerase reporter (Fig.19B). There is also no detectable decrease in
reporter activity by prolonging the treatment of 1,25VD to 6 days in OVCAR3 cells in
which the reporter was stably integrated into the genome (Fig. 19C).
To find out if the putative VDRE interacts with VDR in vivo, ChIP assays were
performed with anti-VDR antibodies. In the soluble chromatin prepared from
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OVCAR3 cells treated with 1,25VD, the anti-VDR antibody precipitated the GADD45
exonic region containing the functional VDRE (Fig. 12B), but could not precipitate
hTERT promoter fragments containing the putative VDRE (Fig. 19D). These data
indicate that VDR is not recruited to the putative VDRE in vivo. It is concluded that in
OVCAR3 cells the putative VDRE in hTERT promoter is not a functional VDRE.
3. The stability of hTERT mRNA is decreased by 1,25VD
The down-regulation of hTERT mRNA after 1,25VD treatment could be due to the
short half- life of the hTERT message. To examine whether 1,25VD- mediated changes in
hTERT mRNA stability contribute to its decreased expression, we performed Real- time
PCR analysis using RNA from actinomycin D-treated cells. After OVCAR3 cells were
treated for 3 days with 1,25VD or vehicle, transcription was inhibited by adding
actinomycin D. At different time intervals, total RNA was isolated and hTERT mRNA
was determined by Real-time PCR analysis. As shown in Figure 20 A, the level of
hTERT mRNA, after norma lization with GAPDH, decreased within approximately 10 hr
in 1,25VD-treated cells, whereas hTERT mRNA from vehicle-treated cells was
comparatively stable over this period of time. The half- life of hTERT mRNA in 1,25VD
treated and control cells is approcimately10 hr and 29 hr, respectively. The same results
were obtained using a sencond probe and primers designed for another region of hTERT
cDNA (Fig. 20B). The rate of degradation of the hTERT mRNA was increased by the
addition of 1,25VD, which demonstrates that the decrease of hTERT mRNA by 1,25VD
is due to its decreased stability.
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Fig. 20. The stability of hTERT mRNA is decreased by 1,25VD. OVCAR3 cells were
-7

treated with 10 M 1,25VD (VD) or ETOH for 3 days, followed by treatment with 5
µg/ml actinomycin D. Total RNA was extracted at 0, 2, 8, 12 hrs and subjected to
Real-time PCR using probe 1 (A) and probe 2 (B), as described in Meterials and
Methods.
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4. Telomerase stably-transfected cells have increased telomerase activity and
prolonged telomere length.
Ectopic expression of hTERT in telomerase- negative human fibroblasts and
endothelial cells resulted in substantial telomerase activity and telomere maintenance.
Furthermore, the ectopic expression of hTERT circumvented senescence and enabled
these cells to be immortalized, i.e, proliferate indefinitely in culture (Hahn, 1999). To
determine the role of telomerase in 1,25VD-induced growth inhibition in OVCAR3 cells,
we tested whether the overexpression of telomerase was sufficient to abolish 1,25VDinduced growth inhibition. hTERT cDNA, under the control of a viral promoter
insensitive to 1,25VD, was stably transfected into OVCAR3 cells. As shown in Figure
21A, the telomerase-OVCAR3 cell lines express 2-4 folds higher levels of telomerase
activity than parental OVCAR3 cells. Telomere length in OVCAR3 cells is ~3 kb as
shown in Figure 21B. This is consistent with results from previous studies showing that
telomere teminal restriction fragments (TRF) are ~3 kb in ovarian carcinoma cells (Villa,
2000; Braunstein, 2001). It has been known that the majority of human cancers have
much shorter telomeres than the corresponding normal tissues; in many cases
approaching that is associated with crisis in normal cells (2-4 kb) (Wynford-Thomas,
1999; Liu, 1999). Telomerase plays an important role in maintaining stable telomere
length. Telomere length in telomerase-OVCAR3 clones was prolonged to 6-10 kb, as
shown in Figure 21B. The ectopic expression of hTERT in OVCAR3 cells dramatically
increased telomerase activity and prolonged telomere length.
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Fig. 21. Telomerase-stably transfected cells have increased telomerase activity and
prolonged telomere length. (A) Proteins were extracted from OVCAR3 cells and
telomerase-OVCAR3 cells and subjected to PCR-TRAP assay, as described in Materials
and Methods. (B) Genomic DNA extracted from OVCAR3 and Telomerase-OVCAR3
were used to measure telomere length. Southern blot hybridization was performed as
described in Materials and Methods.
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or 10 M 1,25VD for 6 days (6 d) or 9 days (9 d). The protein was extracted and
subjected to PCR-TRAP assay, as described in Materials and Methods. (B) Genomic
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DNA extracted from OVCAR3 and Telomerase-OVCAR3 treated with 10 M 1,25VD
(V) or ETOH (E) for 9 days to measure telomere length. Southern blot hybridization was
performed, as described in Materials and Methods.
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In contrast to parental cells, no dramatic decrease of telomerase activity or
telomere length was observed in telomerase-OVCAR3 cells after treatment with 1,25VD
for 6 or 9 days compared with vehicle treatment (Fig. 22 A and B). Cells with ectopic
hTERT expression maintain high telomerase activity after 1,25VD treatment compared
with parental OVCAR3 cells (Fig. 22A). These results demonstrate that ectopic
expression of hTERT is sufficient to protect 1,25VD- inhibition of telomerase activity.
Therefore, these cell lines can be used to determine whether telomerase plays any role
with respect to 1,25VD.
Although 1,25VD dramatically decreased telomerase activity, no remarkable loss
of telomeric repeats was detected after 9 days of treatment with 1,25VD (Fig. 22B). No
decrease in telomere length could be due to the fact that cells undergo only a few
doublings in 9 days, the potential base pair loss in 9 days are estimated to be ~200 bp, the
loss of telomeric repeats may not be measurable by conventional Southern Blotting. A
recent study demonstrated that telomere dysfunction rather than the mean telomere length
was modulated when glutathione (GSH) levels influenced the c- myc-dependent cell death
(Biroccio, 2003). Telomerase and telomere structure are dynamically regulated in normal
human cells and disruption of telomerse activity alters the maintenance of the 3’ singlestranded telomeric overhang without changing the rate of overall telomere shortening
(Masutomi, 2003), suggesting that modulating telomere integrity maybe essential
regardless of telomere length. It is highly possible that although maintaining telomere
length is important, 1,25VD down-regulated telomerase activity could regulate OCa cell
growth through modulation of telomere integrity.
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5. Overexpression of telomerase partially blocks 1,25VD-induced apoptosis
and increases the ability to recover after 1,25VD withdrawal.
To address the question if telomerase participates role in growth-suppressing
activity of 1,25VD in OCa cells, we compared the response of telomerase-OVCAR3
clones to 1,25VD to that of paretal OVCAR3 cells. The effect of 1,25VD on cell growth
as well as the ability to recover from treatment after removal of the hormone was
investigated. Similar to parental cells, growth of telomerase-OVCAR3 cells (Fig. 23)
were also inhibited by 1,25VD, but to a lesser extent. Cells overexpressing hTERT keep
growing in the presence of 1,25VD while the growth of parental cells halted after 6 days
treatment with 1,25VD. Telomerase clones are more resis tant to 1,25VD- induced growth
inhibition. Additionally, after 9 days of 1,25VD treatment, the recovery of telomeraseOVCAR3 cells was rapid compared to the recovery of the parental cell line (Fig. 24). Our
observation suggests that ectopic expression of hTERT in OCa cells protects about 50%
of 1,25VD reduced growth, although other mechanisms independent of telomerase may
also exist.
Since overexpression of telomerase altered cell response to 1,25VD in the
recovery assay, we next assessed whether alterations in apoptotic index occurred.
Parental and telomerase-OVCAR3 cells were treated with 1,25VD and then analyzed by
flow cytometry. As shown in Figure 25, in contrast to the massive apoptosis (70%)
induced in parental cells after 9 days treatment with 1,25VD, telomerase clones showed
fewer apoptotic cells (<40%). The ectopic expression of hTERT partially rescued longterm 1,25VD treated OVCAR3 cells from cell death. This may contribute to
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Fig. 23. Telomerase-OVCAR3 cells are less sensitive to growth inhibition by
1,25VD. OVCAR3 and telomerase-OVCAR3 cells were plated in 96 wells and treated
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with 10 M 1,25VD (VD) or ETOH as a vehicle. Cell numbers were determined with the
MTT assays. Eight samples were analyzed for each data point. *P<0.05 (versus ETOH
treatment).
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Fig. 24. Telomerase-OVCAR3 cells recover quickly from 1,25VD treatment.
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OVCAR3 and Telomerase-OVCAR3 cells were pretreated with 10 M 1,25VD or ETOH
for 9 days. Recovery of pretreated cells was assessed by plating pretreated cells in 96
well plates. Cell numbers were determined with the MTT assay. Eight samples were
analyzed for each data point.
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Fig. 25. Overexpression of telomerase partially blocks 1,25VD-induced apoptosis.
-7

(A) OVCAR3 and Telomerase-OVCAR3 clones were treated with ETOH or 10 M
1,25VD for 9 days. Apoptotic index was determined by flow cytometry and a
representative profile is presented. (B) Bar graphs show percentage of apoptotic cells in
two experiments.
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the reduced growth inhibition of telomerase clones by 1,25VD treatment (Fig. 23).
Collectively, these studies show that in OVCAR3 cells down-regulation of
telomerase is correlated to 1,25VD-induced growth inhibition and apoptosis. The
enhancement of telomerase function in OVCAR3 cells, as measured by telomerase
activity, allows the cells to recover from 1,25VD treatment and rescues them from
1,25VD- induced apoptosis. Telomerase activity remains a key parameter that determines
long-term cell survival in OCa cells. This work supports our hypothesis that telomerase
inhibition by 1,25VD may serve as an effective tool to eliminate OCa cells that have
short telomeres.
EB1089 is more potent than 1,25VD in suppressing OCa cell growth in vitro
and in nude mice.
The effective concentration of 1,25VD (10-7 M) is pharmacological, which is
expected to induce hypercalcemia in vivo. EB1089, a 1,25VD analogue, is less calcemic
and was shown to be more effective against breast (Colston, 1992), pancreatic (Colston,
1997), colon (Akhter, 1996) and prostate (Blutt, 2000) cancers. To test whether EB1089
can be used for long-term treatment and/or chemoprevention of OCa, our study
investigated VDR expression in human ovarian tissues, the growth of OVCAR3 cells and
tumor xenografts in nude mice.
In MTT assays, EB1089 is effective against OCa cells at concentrations 10 times
lower than 1,25VD, making it a promising candidate for in vivo treatment of OCa (Fig.
26 A and B). As expected, EB1089 induced GADD45 reporter activity effectively
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Fig. 26. EB1089 is more potent than 1,25VD in suppressing OCa cell growth.
OVCAR3 cells were plated in 96 well plates and treated 1,25VD (VD) (A) or EB1089
(EB) (B) at the indicated concentrations. Cell numbers were determined with MTT assay.
Eight samples were analyzed for each data point, and the data were reproduced three
times.
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Fig. 27. EB1089 is more effective than 1,25VD in inducing GADD45 reporter
activity. OVCAR3 cells were transfected with 0.2 µg GADDLuc, 0.05 µg pCMVgal,
0.05 µg p91023B-VDR and 0.05 µg pCMX-RXRb and treated with ETOH, 1,25VD or
EB1089 at the indicated concentrations. Luciferase activity was determined and
normalized with cognate β-gal activity.
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at concentrations 10 times lower than 1,25VD (Fig. 27), suggesting a mechanism of
EB1089 action in OCa cells.
To determine whether the effect of 1,25VD and EB1089 on OCa cell growth can
be directly translated into tumor suppression in the whole animal, we tested the effect of
EB1089 in OVCAR3 tumor xenografts. As shown in Figure 28A, EB1089 at 1µg/day/kg
totally inhibited the growth of tumors while a dose of 0.3 µg/day/kg partially inhibited
the growth. Based on statistical analysis of independent samples with the T-test, the
difference between placebo control (6 tumors) and 1.0 µg/day/kg (9 tumors) is significant
(p=0.003). The difference between the 0.3 (6 tumors) and 1.0 µg/kg/day group is also
significant (p=0.04). The difference between placebo control and 0.3 µg/kg was not
significant (p=0.281). This is probably due to the fact that the number of groups was
small and the size of tumors was heterogeneous at the start of the study. In our
experiments, each individual mouse was marked and the tumor volume was recorded
separately; the difference between 0.3 µg/kg/day and placebo is obvious when the growth
of each individual tumor was examined separately.
To determine if EB1089 is less calcemic, serum calcium levels were determined
in treated nude mice (Fig. 28B). Blood tests at 30 days did not reveal significant increase
in blood calcium. The levels in placebo (~9 mg/dl) and both of EB 1089 groups (9~10.5
mg/dl) were within the normal range (7-11 mg/dl). As expected, 1,25VD treatment for
1.0 µg/kg/day induced higher levels of serum calcium (11~12 mg/dl at day-15 and day30), which is outside the normal range. Importantly, no abnormality was seen in mice
treated with EB1089 at 0.3 or 1.0 µg/kg/day for 4 weeks and normal body weight was
maintained (data not shown).
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Fig. 28. EB1089 inhibits OCa xenograft growth.
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Fig. 28. EB1089 inhibits OCa xenograft growth. (A) 2x10 OVCAR3 cells were
injected s.c. into one site in the dorsal side of nude mice. After the tumors grew to 150
3

nm , mice were randomly divided into three groups and treated with placebo or EB1089
at indicated doses daily as described in Materials and Methods. The tomor size was
measured every five days and the growth status of each tumor was recorded separately. *,
p<0.01 compared with placebo group. (B) Average serum calcium levels for each
treatment group.
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VDR and RXR are expressed in precursors for epithelial OCa and normal
ovarian surface epithelial cells are responsive to 1,25VD.
If 1,25VD is useful for OCa prevention, its receptors should be expressed in OSE
cells and benign ovarian tumors, the precursors for malignant epithelial OCa, which gives
rise to more than 90% of human OCa. Indeed, our immunohistochemical studies showed
that both VDR and RXR are expressed strongly in human OSE cells and in benign
tumors. Skin tissues which express VDR and RXR were used as positive control and the
primary antibody was substituted with IgG as negative control (Fig. 29).
To test whether normal ovarian surface epithelial (OSE) cells respond to
1,25VD’s growth suppression, primary human OSE cell cultures were treated with ETOH
or 1,25VD and their growth was analyzed by the MTT assays. As shown in Figure 30, the
growth of human OSE cells was suppressed by 1,25VD in a similar way as seen with
OVCAR3 cells. These data clearly demonstrate that human primary ovarian cells are
sensitive to 1,25VD.
Collectively, the expression of VDR in human ovary and the growth inhibition of
human primary OSE by 1,25VD indicate that 1,25VD analogue could also be used for
chemoprevention.
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Fig. 29. Normal ovarian epithelial cells and benign adenomas express VDR and
RXR. Paraffin sections of tissues were stained with anti- VDR (rat monoclonal 9A7) or
anti-RXR (rabbit polyclonal) antibodies. The anti- RXR antibody was generated against
RXRα, but also cross reacts with RXRβ and RXRγ. IgG controls were performed with
normal ovarian sections (rat IgG for VDR and rabbit serum for RXR).
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Fig. 30. 1,25VD suppresses human primary ovarian cell growth. Human primary
ovarian epithelial cells were plated in 96-well plates and treated with 10-7 M 1,25VD
(VD) or ETOH. Cell numbers were determined at the indicated times by the MTT assays.
Eight samples were analyzed for each data point. * P<0.05 (versus ETOH treatment).
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DISCUSSION

To demonstrate the role of 1,25VD and it analogues in OCa treatment and
prevention, the mechanism by which 1,25VD mediated its antiproliferative activity was
explored using a VD sensitive OCa cell line (OVCAR3) as a model system. The effect of
the 1,25VD analogue EB1089 on OCa cell growth was also investigated in vitro and in
vivo. Cell cycle studies showed that 1,25VD increased the proportion of OVCAR3 cells
in the G0/G1 and G2/M phase and decreased those in the S phase. 1,25VD also induced
apoptosis in OVCAR3 cells.
Furthermore, we have identified GADD45 and telomerase as target genes for
1,25VD and suggest a model of VD action in OCa cells (Fig. 31). 1,25VD induces
binding of the VDR/RXR heterodimer to the VDRE located in the fourth exon of
GADD45 gene at a position downstream from the termination codon for protein
translation. Presumably through the recruitment of co-activator complexes, the activated
VDR/RXR interacts with the Pol II complex bound to the promoter and increases the rate
of GADD45 transcription. This leads to an increase in the amount of GADD45 protein
that, through a yet unknown undefined mechanism, decreases the level of cyclin B, the
regulatory subunit of cdc2 kinase. The resulting decrease in cdc2 activity is then
responsible for disturbed cell cycle progression to M phase. In addition, 1,25VD inhibits
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Fig. 31. Model for the integrated cellular pathways of 1,25VD action in OCa cells
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telomerase activity by decreasing the stability of hTERT mRNA, not by the putative
VDRE in the hTERT promoter which is not functional in vivo. Importantly, hTERT
clones are more resistant to 1,25VD- induced apoptosis and growth inhibition. In contrast
to parental cells that recover slowly from prolonged treatment with 1,25VD, hTERT
clones re- grow quickly after 1,25VD withdrawal. Lastly, our investigation of the
antiproliferative effects of EB1089 on OVCAR3 cells and xenografts without inducing
hypercalcemia may indicate a novel preventive and therapeutic option fo r the treatment
of OCa.
Upregulation of GADD45 by 1,25VD is mediated through a novel exonic
enhancer
Induction of GADD45 can be detected in cells within 2 hrs of treatment with
1,25VD (Fig. 8B). With the lack of a VD effect on mRNA stability (Fig. 8C) and the
identification of functional VDREs in the genome (Figs. 9-12), our data establish
GADD45 as a primary and immediately early response gene for 1,25VD. Furthermore,
our data suggest that GADD45 regulation is mediated through a VDR/RXR heterodimer,
instead of a VDR/VDR homodimer. This conclusion is reached based on the inability of
VDR to bind to all putative VDREs in EMSAs until the addition of RXR and the upshifting of the complexes by RXR antibody (Fig. 9). At variance with the belief that
nuclear receptors forming heterodimers with RXRs bind DNA in the absence of ligand,
our ChIP assays (Fig. 12B) clearly show that in vivo binding of VDR to the exonic
VDRE is ligand-dependent. Recently, Yamamoto et al. (2003) reported a similar
observation on VDRE located in the promoter of the OPN gene, suggesting that the
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ligand dependency is common to VDREs located inside and outside the promoter
regions.
Since p53 in OVCAR3 cells is mutated (Yaginuma, 1992), the regulation of
GADD45 transcription by 1,25VD obvious ly occurs independently of p53 activity. This
is consistent with the identification of the VDRE in the fourth exon that is distant from
the p53 binding site which is located in the third intron (Hollander, 1993). This is also
consistent with the conclusion reached by a study of squamous cell carcinoma
(Prudencio, 2001). Furthermore, the VD regulation of GADD45 is also likely to be
independent of BRCA1 since the DNA element for this tumor suppressor is located in the
promoter region (Jin, 2000). It is striking that four of the five putative VDREs bound
VDR/RXR equally well in EMSAs, but only VDRE- E mediated the up-regulation of
GADD45 reporter by 1,25VD. The other putative VDREs are either nonfunctional or
may act in a negative way. Overall, the data suggest that the regulation of GADD45 by
1,25VD is a complex process that may involve the interaction of the receptor bound to
the VDRE and other transcription factors. The different VDREs may also function in a
cell-specific manner to mediate the regulation of GADD45 expression by 1,25VD.
GADD45 protein upregulation by 1,25VD is required for the hormone induced cell cycle arrest at the G2/M but not the G1/S checkpoint
Our studies link GADD45 induction specifically to the inhibition by 1,25VD of
cell cycle progression through the G2/M checkpoint. This linkage was established using
cells in which GADD45 expression was compromised by the anti-sense approach or
genetic knock out. It is important to determine the effect of GADD45 anti-sense on
1,25VD- induced growth inhibition in the stably transfected cells, which would reveal
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whether G2/M arrest is a major or minor factor in the overall growth inhibition. However,
our analysis with MTT assay revealed little difference in the overall response to 1,25VD
between anti-sense GADD45 and control clones (data not shown). This may due to cell
cycle arrest being shifted from G2/M to G1/S checkpoint in anti-sense clones.
Previous studies (Akutsu, 2001) have shown that GADD45 induction in
squamous cell carcinoma by 1,25VD is associated with an increased interaction with
PCNA. Although we have not examined the association of GADD45 with PCNA, this
seems unlikely in OVCAR3 cells. PCNA is required for DNA replication in S phase but
our data show that G1/S arrest still occurs in OVCAR3 cells expressing the anti-sense
cDNA of GADD45 (Fig. 13C and 13D). Instead of PCNA, our studies show a 1,25VDinduced decrease in cdc2 activity, which is associated with a decrease in the level of
cyclin B1 protein. The decrease was not observed in the stable clones expressing
GADD45 anti-sense cDNA (Fig. 15). The data suggest that GADD45 mediates the effect
of 1,25VD on cdc2 activity. Our data concur with the proposed role of GADD45 in G2/M
arrest induced by certain types of DNA damaging agents (Wang, 1999; Zhan, 1999).
Zhan et al. (1999) have shown that GADD45 inhibits the interaction between cyclin B
and cdc2. Later, it was shown that GADD45- induced cell cycle arrest at G2/M is
associated with an altered cellular distribution of cyclin B1 (Jin, 2002), which seems to
require a functional p53. Our conclusions, however, differ from the above studies since
we detected a decrease in the level of cyclin B1 protein (Fig. 15). As mentioned earlier,
OVCAR3 cells contain a mutant p53 (Yaginuma, 1992). Obviously, GADD45 exerts its
effect on cdc2 activity and the G2/M transition in the OCa cells independently of p53. It
remains to be determined whether the effect of 1,25VD on G2/M in OCa cells is exerted
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through GADD45 alone or in combination with another protein that functions similarly to
p53.
Besides its role in regulating G2/M transition, GADD45 plays an essential role in
DNA repair and in the maintenance of genomic stability. MEFs derived from GADD45null mice exhibit aneuploidy, chromosomal abnormalities, gene amplification and
centrosomal amplification (Hollander, 1999). GADD45-null mice display increased
sensitivity to dimethylbenzanthracene-induced carcinogenesis (Hollander, 2001). It is
intriguing that dimethylbenzanthracene increased female ovarian tumors more efficiently
in GADD45-null mice than wild type (Hollander, 2001). GADD45 induction by 1,25VD
through VDR suggests that VDR may act in a p53 independent tumor-suppressing
pathway to affects ovarian genomic stability. Along this line, VDR has been shown to act
as a bile acid sensor for the secondary bile acid lithocholic acid (LCA) (Makishima,
2002), a potential enteric carcinogen that induces DNA strand breaks, forms DNA
adducts and inhibits DNA repair enzymes. It will be interesting to show whether ovarian
carcinogens or DNA-damaging processes (e.g. ovulation) activate VDR in ovarian
epithelial cells and, if yes, whether the VD- independent VDR activation functions in
DNA repair.
Down-regulation of telomerase by 1,25VD is mediated through
destabilization of hTERT mRNA
Hormones regulate the expression of telomerase in hormone-responsive cell
systems. In some cases, induction or repression of telomerase has been considered a
consequence of maturation and/or growth arrest, rather than a direct hormonal effect. For
example, androgens stimulate telomerase indirectly since the hTERT promoter construct
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was not activated by androgen and transcription of the endogenous gene was not
stimulated early enough in cultured cells to be considered a direct target of androgens.
However, it has also been reported that inhibition of telomerase activity is an early event
of the differentiation process in leukemia cells rather than its consequence (Albanell,
1996; Savoysky, 1996). Retinoids and VD negatively regula te telomerase that is
associated with differentiation in leukemia cells. However, it is not yet clear at which
level of gene expression this down-regulation occurs. In addition, numerous studies
showed that hormones directly regulate telomerase via different mechanisms. For
example, estrogens activates telomerase through the direct interaction of ligand-activated
ER with the ERE in the hTERT promoter. Progesterone regulates hTERT transcription
via the MAP kinase cascade.
There was a significant correlatio n of telomerase activity with hTERT mRNA
expression but not with TP1 or hTR. hTERT is the major determinant of telomerase
activity (Counter, 1998). In our study, the repression of telomerase activity by 1,25VD
accompanied down-regulation of hTERT mRNA as shown by RT-PCR and confirmed by
Real-time PCR.
The present study demonstrates that 1,25VD down-regulates telomerase activity
mediated through repression of hTERT mRNA (Fig. 17-20). The stability of hTERT
mRNA was decreased by 1,25VD (Fig. 20), demonstrating that the regulation was
posttranscriptional. Our findings provide direct evidence that hTERT is a target gene for
1,25VD.
Although EMSA revealed that the putative VDRE bound specifically to the
VDR/RXR heterodimer, as shown by Ikeda et al, 2003, it is worth noting that in their
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study, this VDRE only mediated the down-regulation of reporter activity by cotreatment
of 1,25VD and 9-cis RA, but not 1,25VD alone. The limitation of this VDRE function
may due to different cellular context. Transcriptional assays using luciferase reporter
plasmids containing full length of hTERT promoter showed no down-regulation by
1,25VD or by combination of 1,25VD and 9-cis RA in OCa cells. Furthermore, ChIP
analysis showed that no detectable binding of VDR to this VDRE in vivo. All these data
indicate that this putative VDRE is not functional in OVCAR3 cells. Real-time PCR
analysis revealed that 1,25VD decreased the stability of hTERT mRNA.
Real-time PCR showed that hTERT mRNA was degraded to

50% within ~10 hr

by treatment of 1,25VD, while no detectable increase in the number of apoptotic cells
within this timeframe (data not shown). The time course of destabilization of hTERT
mRNA by 1,25VD precedes induction of apoptosis by 1,25VD, suggesting that decreases
in hTERT mRNA are not a result of the induction of apoptosis in these cells.
To our knowledge, this is the first study incident showing that the stability of
hTERT mRNA was regulated. This may open new aspects to study the regulation of
hTERT, especially in the repression of telomerase.
Sequence analysis of the hTERT promoter revealed binding sites for several
transcription factors suggesting hTERT could be regulated by different factors in
different cellular contexts (Cong, 2002). The oncogene c-myc has been shown to activate
telomerase through two myc binding sites in hTERT promoter (Wu, 1999). Since 1,25VD
have been shown to inhibit c-myc (Saunders, 1993) and c-myc binding sites are present in
full- length hTERT reporter construct, this oncogene could mediate the repression of
telomerase by 1,25VD. However, the persistent inhibition of hTERT mRNA in the
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presence of cycloheximide and the lack of inhibition in reporter assays rule out the
indirect effect of 1,25VD mediated through c-myc.
Over-expression of hTERT allows the recovery of OCa cells after 1,25VD
treatment and partially relieves 1,25VD-induced apoptosis
Treatment of 1,25VD in parental OCa cells causes massive apoptosis leading to
the loss of the entire population. In addition to the decrease of telomerase activity,
apoptosis was also induced by 1,25VD and the recovery from 1,25VD treatment was
slow in parental OVCAR3 cells. By contrast, the hTERT-overexpressing cells maintained
telomerase activity at higher levels and telomere length at a size much longer than
parental cells over time, 1,25VD- induced apoptosis and growth inhibition were partially
rescued, leading to cell recovery and growth (Fig 21-25). This indicates that a certain
level of telomerase activity may play an important role in protecting cells from apoptosis
in OCa cells. Our results provide the first direct evidence that telomerase may affect
1,25VD- induced apoptosis in OCa cells.
It is well known that there is strong correlation between telomere function and
senescence (Kolquist, 1998). Telomerase activation is shown as one of the three steps
needed to overcome senescence and transform normal human epithelial cells to cancer
cells (Hahn, 1999). Cells undergoing senescence have a large and flat morphology,
express acidic beta-galactosidase (β-gal) and show a permanent G0/G1 arrest, whereas
apoptotic cells show evidence of DNA fragmentation (Biroccio, 2003). Many studies
have linked telomerase inhibition to apoptosis. For example, hTERT-expressing cells
were more resistant to apoptosis induced by UV and γ- irradiation (Gorbunova, 2002).
Following ectopic expression of dominant- negative TERT into transformed cells, growth
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inhibition and apoptosis was induced (Hahn, 1999; Zhang, 1999). In our model system,
1,25VD- induced decrease in telomerase activity is correlated with 1,25VD- induced
apoptosis, not senescence. This is supported by our data that the senescence β-gal, a
marker for senescence, was not induced by 1,25VD treatment in OCa cells (data not
shown). Instead, extensive cell death was observed. Our data strongly suggested that
telomerase plays a critical role in cellular resistance to apoptosis.
Little is known about the signaling pathways mediating VD- induced apoptosis.
Several factors involving mitochondrial and caspase changes were investigated. Bcl-2 is
down-regulated in VD- induced apoptosis in breast and prostate cancer cells (Mathiasen,
1999; Blutt, 2000), pro-apoptotic Bak is induced in colon cancer cells (Diaz, 2000). VD
induced–apoptosis is caspase-dependent in prostate cancer cells, while in breast cancer
cells, calpain may replace caspases as a key mediator (Mathiasen, 1999 and 2002).
It is assumed that some anti-apoptotic pathways are activated by telomerase or
that the apoptotic pathway induced by 1,25VD is blocked by telomerase overexpression.
As suggested in a recent report, overexpression of wild-type hTERT in HeLa cells
increases their resistance to apoptosis, induced by the DNA damaging agent etoposide,
and TERT suppresses apoptosis at a premitochondrial step by a mechanism requiring
reverse transcriptase activity and 14-3-3 protein-binding (Zhang, 2003). Overexpression
of Bcl-2 and the caspase inhibitor zVAD- fmk protected cells against apoptosis in the
presence of telomerase inhibitors in pheochromocytoma cells (Fu, 1999). All these data
suggest that the telomerase function is upstream of caspase activation and mitochondrial
dysfunction. But different from those DNA damaging reagents- induced apoptosis,
1,25VD induced apoptosis could mediate through different pathway. It will be
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worthwhile to study how telomerase inserts anti-apoptotic function to block 1,25VDinduced apoptosis.
Transformed human cells enter crisis once TRF reach a length of ~4 kb.
Telomeres that have been shortened to this degree may no longer protect chromosome
ends, and in turn, may lead to the genomic instability and cell death (Counter, 1998). This
is consisted with the fact that many cancers have mean telomere lengths well below
normal and often close to the threshold required for cell survival. Tumor cells, such as
OVCAR3 cells, have very short telomere and appear to require telomerase activity even
for short-term viability. In OVCAR3 cells, the short telomere length of 3 kb is close to
the threshold level and was maintained by high telomerase activity. It is postulated that
in these cells telomerase activity is required at nearly every division of cells replicating
with critically short telomeres and inhibition of telomerase activity in these cells causes
loss of viability through activation of apoptotic pathways (Zhang, 1999).
It is known that telomerase inhibition may lead to a phenotypic lag in which cells
would continue to divide until the point at which the telomeres became critically short.
This lag phase varies depending on the initial telomere length. In terms of telomerase as
anti-cancer target for VD, OCa cells, which have short telomeres, could have short lag
phase and thus be efficiently inhibited by VD.
1,25VD analogue EB1089 has potent anti-tumor activity in vitro and in vivo,
and has strong implications to cancer treatment and prevention
Since the pharmacological levels of 1,25VD (10-7 M) induce hypercalcemia, the
goal of our research is to establish synthetic 1,25VD analogues, such as less calcemic
EB1089, as chemotherapeutic treatment for OCa.
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Our study is the first to demonstrate EB1089 inhibits growth of OCa cells and
tumor xenografts in nude mice. Importantly, the tumor inhibition in vivo occurred without
physical symptoms of hypercalcemia, and particularly promising is the minimal effect on
serum calcium (Fig. 28). It demonstrates that EB1089 may be suitable for long-term
treatment and/or chemoprevention.
EB1089 could also be useful for treating VD-resistant cancers. A recent study
demonstrated that down-regulation of 24- hydroxylase enhaced 1,25VD levels and
improved mitotic control of tumor cells (Cross, 2003). The rapid breakdown of 1,25VD
was suspected to be the cause of the resistance of DU145, a prostate cancer cell line, to
1,25VD. In the presence of the 24-hydroxylase inhibitor, growth of DU145 cells was
inhibited by 1,25VD and as much as in LNCaP cells (Zhao, 2001). EB1089 has 50-fold
lower affinity than 1,25VD for 24-hydroxylase, and it is more slowly inactiviated by 24hydroxylasion (Roy, 1995), supporting the potential effect of EB1089 in the treatment of
VD-resistant cancers.
The pathogenesis of epithelial OCa is not completely understood, but it is
believed that the process of recurrent ovulation (incessant ovulation) causes genetic
damage to ovarian epithelial cells and that sufficient genetic damage can lead to OCa in
susceptible individuals (Rodriguez, 2003). According to this model, reproductive and
hormonal factors, including VD, retinoids, and non-steroidal anti- inflammatory drugs,
may decrease OCa risk via their inhibitory effects on ovulation, leading to the biologic
effects on the ovarian epithelium that are cancer preventive. Along this line, VDR
expression is required for 1,25VD- mediated growth effects. We have shown the
expression of VDR and its heterodimer partner, RXR, in human ovary and the response
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of primary human ovarian cells to 1,25VD. These data indicate that the human ovary is a
VD responsive organ and can be impacted strongly by “environmental” VD, leading to
decreased OCa risk.
Most tumors have compromised p53 function and half of OCa are estimated to
have lost p53 function, thus becoming refractory to drugs targeting p53 pathways.
Examination of p53- independent response in p53- mutant OVCAR3 cells warrants closer
attention. These tumors may however still be sensitive to synthetic VD since 1,25VD
induces GADD45 and inhibit telomerase in a p53- independent manner. Better
understanding of the molecular mechanism of VD is critical for determining the ultimate
utility of 1,25VD analogues in the clinic.
In conclusion, molecular studies show that 1,25VD inhibits OCa cell growth and
is mediated through regulation of specific genes including GADD45 and telomerase. Our
preclinical data show that 1,25VD analogue reduces OCa development in animals. Data
from normal human ovarian tissues and cells demonstrate the presence of VDR and a
response to 1,25VD. Studies from cellular, molecular and animal levels strongly suggest
that VD represents a molecular target for chemotherapy and chemoprevention of OCa.
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SUMMARY AND THE PERSPECTIVES OF FUTURE STUDY

OCa is a deadly disease and its etiology is largely unknown. Lack of both reliable
detection methods and early symptoms results in poor prognosis for patients with OCa.
Relapse and resistance to current treatment necessitate the development of new
therapeutic methods to fight this deadly disease. Our studies on VD action in OCa
suggest that 1,25VD and its synthetic analogues may be effective therapeutic treatments
for OCa.
GADD45 is identified as one of the primary target genes by 1,25VD in OCa cells.
Based on the similarity to concensus sequences, several putative VDREs identified by
EMSA are localized in GADD45 introns or exons but not in the promoter region.
Receptor response elements usually lie in the promoter region of regulated gene and all
known VDRE have been identified in the promoter. Of particular interest to our study is
VDRE in the 3’ untranslated region of exon 4 plays critical role in mediating the
transcriptional regulation of GADD45. To our knowledge, this is the first study showing
that a vitamin D enhancer element is localized in the exon region. Our study can not
exclude that other VDREs act in a negative way and that different VDREs in the
GADD45 genome may function in a cell-specific manner to mediate the regulation of
GADD45 expression by 1,25VD.
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Since the specific VDRE is located in an exon and falls into the 3’ untranslated
region og GADD45, it provides an excellent model system to study how DNA response
elements in the 3’ end of the coding sequence may regulate the transcription of a target
gene via the Pol II complex which bound to the promoter at the 5’ end. Site-specific
transcription factors (Agalioti, 2002), including nuclear hormone receptors (Louie, 2003),
recruit components of the Pol II complex to the enhancer sequences and, after coactivator mediated chromatin remodeling, the adjacent nucleosome slides downstream to
initiate transcription. It remains to be seen whether DNA response elements at the 3’ end
of the coding sequence recruit Pol II components and, if so, how the modified
nucleosome moves to the correct position to permit initiation of transcription since the
nucleosome has to either slide upstream by a significant distance or jump across the
coding region to initiate transcription.
VD-dependent apoptosis and cell cycle arrest could engage activation of the p38
MAPK pathway and induction of GADD45 (Sutter, 2003). Recent data showed that
GADD45 is reqired for p38 activation. Disruption of GADD45 abrogates H-ras induced
cell-cycle arrest and p38 activation (Bulavin, 2003). It is quite likely that upregulation of
GADD45 by 1,25VD is required for activation of p38, that may mediate 1,25VD- induced
growth inhibition. In support this hypothesis, it is known that most biological actions of
VD are mediated through the nuclear VDR-mediated expression of target genes. The
study of VDRKO mice showed that nongenomic effects of VD in osteoblasts are
abrogated in the absence of nuclear VDR (Erben, 2002) and suggest that some
nongenomic responses require a functional nuclear VDR. Using GADD45 as a model
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system, future work may decipher the cooperation of nongenomic and genomic effects of
VD.
Given that telomerase activity is regulated at multiple levels by different stimuli,
including hormones, the mechanisms involved in telomerase regulation are far from
established. Our data addressed a novel mechanism of down-regulation of telomerase by
1,25VD. Better understanding of the regulation of telomerase by 1,25VD will provide the
basis for telomerase activity in VD-targeted therapy.
Although hTERT is regulated tightly at the promoter machinery and a putative
VDRE in the hTERT promoter responds to a combination of 1,25VD and 9-cis RA in
certain prostate cancer cells, it fails to respond to 1,25VD alone (Ikeda, 2003). It is not
unusual that sequences match in vitro but do not provide a functional VDRE (Colnot,
2000; Gonzalez, 2002). We provide strong evidence that VD increase the degradation of
hTERT mRNA by real-time PCR analysis using 2 probes. Our study is the first to
demonstrate down-regulation of telomerase mediated by decreasing the hTERT mRNA
stability.
Given that upregulation of hTERT mRNA and telomerase activity induced by
multiple oncogenetic factors in cancer cells, degradation of hTERT mRNA by 1,25VD
could be an effective way to suppress the effect of multiple oncogenic pathways in OCa.
Recent studies showed that double-stranded RNA, including small interfering
RNA (siRNA) and microRNA (miRNA) can induce the degradation of homologous
RNAs in organisms as diverse as protozoa, animals, plants and fungi, resulting in
posttranscriptional gene silencing (Lewis, 2003). MiRNA are endogenous ~22nt RNAs
that arise from larger precursors transcribed from non-protein-coding genes. SiRNA arise
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by cleavage of long, double-stranded RNAs. Despite the differences in origin, miRNA
ans siRNA are functionally interchangeable (Carrington, 2003; Nelson, 2003). 1,25VD
induced degradation of hTERT mRNA may provide a model to study the
posttranscriptional repression of hTERT mRNA by double-stranded RNA. hTERT is not
included in those ~400 targets of mammalian miRNA identified in the present database,
perhaps due to the limited sensitivity of current bioinformatic methods. The actual
number of target genes regulated by each miRNA is likely to be substantially higher
(Lewis, 2003). It remains to be seen if hTERT would be a target for miRNA; if so, it will
be important to establish how 1,25VD mediates down-regulation of hTERT mRNA
through MiRNA.
The ability of 1,25VD to induce cell cycle arrest and apoptosis without the
involvement of p53 may prove useful in therapy. It is known that p53 stimulates the
activities of p21/WAF1, gadd45 and bax genes to enhance their expression as a
transcriptional factor resulting in cell cycle arrest, DNA repair and apoptosis (Bargonetti,
2002). p53 is mutated in 50% of human malignancies, including ovarian cancer and
tumors with mutant p53 resist conventional p53-target therapy. In our nodel system,
1,25VD stimulates GADD45 and down-regulates telomerase in a p53- independent
manner. 1,25VD therapy might compensate or substitute for part of the p53 function to
induce cell cycle arrest and apoptosis. 1,25VD may prove valuable candidates for treating
OCa, especially those OCa that have acquired resistance to other apoptosis- inducing
agents due to a mutation in p53.
VD decreases the generation of single-strand DNA induced by diethylnitrosamine
(DEN), a mutagen that induces chromosome aberrations (Basak, 2000). DNA double
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strand breaks are generated from mutagen- induced DNA lesions in the S-phase of the cell
cycle. It is reasonable to assume that double strand breaks are repaired in the G2 phase by
post-replicational repair mechanism. Therfore, VD- mediated suppression of double
strand breaks could be mediated through GADD45, which has been shown to play role in
DNA repair. GADD45 modified DNA accessibility on damaged chromatin (Carrier,
1999) and affects chromatin remodeling of templates concurrent with DNA repair.
Slower nucleotide excision repair was found in GADD45 deficient keratinocytes exposed
to UV (Maeda, 2002). Based on these data GADD45 may participate in the coupling
between chromatin assembly and DNA repair. Since telomerase maintains the telomere
length and contributes to chromosome stability (Cech, 2004), it will be worthwhile to
investigate the role of GADD45 and telomerase in VD-protected chromosome stability
and induced DNA repair. These two pathways will provide useful targets for DNAdamaging chemotherapeutics against p53-defective OCa, which have decreased ability to
repair chemotherapeutic damage.
We were first to provide preclinical data on the 1,25VD analogue EB1089 in
OCa. The goal of future studies is to test EB1089 or other promising 1,25VD analogues
in clinical trial of OCa. To increase the antiproliferative potency without increasing side
effects, use of less calcemic analogues appears to be the most reasonable approach.
Several promising new synthetic VD analogs are also under development, such as KH1060, LG190119, deltanoids, 1-alpha- hydroxyvitamin D5, vitamin D2, QW-1624F2-2,
etc.
EB1089 has been widely used in breast and colon cancer patients and stabilization
of disease was observed in a phase I trial (Gulliford, 1998). In a phase II study of EB1089
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in patients with inoperable hepatocellular carcinoma, strikingly, out of 33 patients, two
had complete response, 12 stable diseases. Complete regression appeared after 6 and 24
months of treatment and lasted 29 to 36 months (Dalhoff, 2003). EB1089 was also well
tolerated. Most patients tolerated a daily dose of 10 µg of EB1089. A Phase III trial in
hepatoma are currently ongoing. These studies showed EB1089 response by a reduction
of solid tumor size and provide the rationale that EB1089 can be used for treatment. The
effectiveness of 1,25VD analogues in slowing the progression of prostate cancer, was
shown in a study of an oral 1,25VD analogue (Rocaltrol) to treat early recurrent prostate
cancer. PSA doubling time was significantly prolonged by the treatment in all 7 cases
(Zhao, 2001).
Administration of 1,25VD analogues through dietary supplementation suggests
that oral ingestion of VD-based chemotherapy is an effective and feasible approach. Oral
administration and long-term safety of 1,25VD analogues clearly has the advantage in
terms of feasibility of cancer chemotherapy and chemopreventive agents (Welsh, 2003).
Our study showed human OSE growth was inhibited by 1,25VD and that VDR,
RXR are expressed in normal human ovary tissues, which support the suspected role of
VD in OCa initiation. Our data suggest that VD may have a cancer preventative effect.
While numerous issues remain to be addressed, it is essential to investiga te the anti-tumor
activity in the OCa “prevention” model after defining the downstream targets of VDR in
the normal ovary.
In summary, we link the specific molecular pathway to 1,25VD’s biological
function in this study. We provide the first molecular evidence that G2/M arrest by
1,25VD in OCa cells is mediated through the induction of GADD45 via a novel exonic
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enhancer. We are also first to show that 1,25VD induced-apoptosis is mediated by
destabilization of hTERT mRNA and a decrease in telomerase activity. In addition, our
study is the first to demonstrate that 1,25VD analogue EB1089 inhibits OCa xenograft in
vivo. With the ubiquitous expression of VDR and RXR in ovarian tissues and response of
primary OSE to 1,25VD, our data strongly suggest further investigation of less calcemic
synthetic 1,25VD analogues as chemopreventive and chemtherapeutic agents against
OCa. Furthermore, half of OCa is estimated to lose p53 function, thus becoming
refractory to drugs targeting p53 pathways. These tumors may however still be sensitive
to synthetic VD since 1,25VD induces GADD45 and inhibits telomerase in a p53independent manner.

112

MATERIALS AND METHODS

Materials
pHG45-HC containing the 8 kb genomic sequence of human GADD45
(Hollander, 1993), pCMV45 containing the open reading frame of human GADD45
cDNA and pCMVAS45 containing human GADD45 cDNA in the anti-sense orientation
(Zhan, 1994), pCMVgal (Li, 2003), p91023B-VDR (Baker, 1988; Hilliard, 1994),
pCMX-RXRβ (Mangelsdorf, 1992), p23 containing rat 24- hydroxylase promoter in
pMAMMneoLuc (Arbour, 1998) and pBabhTERT (Vaziri, 1998) hTERT reporter
construct pGL3-3328Luc (Kyo, 1999)have been described previously. pGL3-promoter,
pGL3-basic and pGL3-control vectors were from Promega (Madison, WI). MEFs from
wild type and GADD45- null mice have been described (Hollander, 1999). 1,25VD was
from Calbiochem (La Jolla, CA). EB1089 was kindly provided by Dr. Binderup of Leo
Pharmaceuticals Products (Ballerup, Denmark). Baculovirus-expressed human VDR
protein, human RXRβ protein and anti-RXRβ antibody were from Affinity BioReagents
Inc. (Golden, CO). Anti- VDR antibody was from Chemicon International (Temecula,
CA). Anti-Flag M2 antibody and anti-β-actin antibody were from Sigma (St. Louis, MO).
Anti-GADD45 antibody (C-20), ant i-cdc2 antibody and anti-cyclin B1 antibody (D11)
were from Santa Cruz Biotech (Santa Cruz, CA). All oligonucleotides were synthesized
by Invitrogen (Carlsbad, CA). The sequence of primers used for the construction of
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GADDLuc reporter by polymerase chain reaction (PCR) is: 5’GGTGGTACGCGTCCCGAACTTCTCTTACCTACC-3’ (forward) and 5’GGTGGTAGATCTACCCAAACTATGGCTGCACAC-3’ (reverse). The sequence of
the oligonucleotides in sense orientation for producing complementary double strand
oligoes for EMSA and site- mutagenesis is listed below: human OC VDRE 5’ –
ttggtgactcaccGGGTGAacgGGGGCAtt- 3’; putative GADD45 VDRE-A 5’ –
ttgggcgtgcagGGGTCAtggGGGGTGacg- 3’; putative GADD45 VDRE-B 5’ –
taggtggGGGTCAggaGGGTGGctgcctttgt- 3’; putative GADD45 VDRE-C 5’ –
aactGTTTCActcAGGTCAgggtaacaagt- 3’; putative GADD45 VDRE-D 5’ –
cagcttgGGTTGCatgGGTTCAgactttgc- 3’; putative GADD45 VDRE-E 5’ –
gccaaggGGCTGAgtgAGTTCAactacatg- 3’; putative hTERT VDRE 5’ –
cacccactggtaaggAGTTCAtggAGTTCAat- 3’; primer for the mutation of VDRE-A 5’ –
gtgcagGGGTCAtggGGGtTtacggggccgcggga- 3’; primer for the mutation of VDRE-B 5’
–GGGTCAggaGGGTttctgcctttgtccgactagagtg- 3’; primer for the mutation of VDRE-D 5’
–cagcttgGGTTGCatgGGTTttgactttgcaatgtgtag- 3’; primer for the mutation of VDRE-E
5’ –gccaaggGGCTGAgtgAGTTttactacatgttctggg- 3’. Capital letters are used to indicate
the hexameric core binding motifs in the VDRE primers and bold letters in lowercase are
used to indicate the nucleotides in the mutagenesis primers that are different from the
wild type sequence. The sequence of primers for chromatin immunoprecipitation (ChIP)
assays is listed below: VDRE- E region (2565/2767) -CTGAACGGTGATGGCATCTG3’ (forward) and 5’ -CTGTTTCAACACAGCTTCCTTC- 3’ (reverse); promoter region-1
(-1492/-1241) 5’-GTTGTCCATGGCTGACAACA-3’ (forward) and 5’GCTCCCACATGCTTGCATTC-3’ (reverse); promoter region-2 (-505/-310) 5’-
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CACTTCTGAGGTAAACTTTGC-3’ (forward) and 5’GAAGCAGGCTGCCAAGTGTT-3’ (reverse).
Colorimetric methylthiazole tetrazolium (MTT) assays and statistical analysis

To measure cell growth, OVCAR3 cells were plated at 2 × 103 cells/well in 96well plates and treated with VD or vehicle. MTT assays were performed as described (Li,
2001). OD595 was read on a MRX microplate reader (DYNEX Technologies, Chantilly,
VA).
For cell growth and cell cycle analyses, statistical analysis was performed using
the independent-samples t test. P< 0.05 was considered to be statistically significant.
Cell cycle and apoptosis analysis by flow cytometry
To determine the cell cycle distribution, cells were harvested by trypsin digestion
and fixed with 70% ethanol in PBS for 12 hours at 4 o C. Fixed cells were incubated
overnight with 100 µg/ml RNase, stained with 50 µg/ml propidium iodide at 4 o C and
subjected to cell cycle analysis on a FACScan (Becton Dickinson, Mountain View, CA).
To determine the apoptosis, cells were harvested by trypsin digestion and washed with
PBS. Cell suspension in 1x assay buffer was added annexin V-FITC and propidium
iodide and incubated for 15min, then subjected to flow cytometry.
Northern blot analysis
To determine the level of GADD45 mRNA, Northern blot was performed as
described (Zhang, 2003). Briefly, OVCAR3 cells were incubated with 1,25VD or vehicle
for the indicated times. Total cellular RNA was isolated by TRIzol (Invitrogen) method
following manufacture’s instruction. Samples containing 20 µg RNA were run on a 1%
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agarose gel in denaturing gel buffer (Ambion, Austin, TX) and transferred onto a nylon
membrane. The membrane was pre- hybridized at 65 o C for 4 h and hybridized with the
GADD45 or GAPDH probe at 65 o C for overnight. Washes were performed in high
stringency buffers. To prepare GADD45 probe, full- length GADD45 cDNA was released
from pCMV45 vector with HindΙΙΙ/XbaΙ digestion, separated and recovered from agarose
gel. GAPDH probe was from Ambion. The probes were labeled with

32

P using random-

primed DNA labeling kit (Ambion). Signal densities were analyzed with scion Image
software (Scion Corp., Frederick, MD).
Gel mobility shift assay (EMSA)
EMSA was performed as described (Li, 2003; Gonzalez, 2002) with
modifications. Briefly, double-stranded oligonucleotides were end-labeled with

32

P using

a T4 polynucleotide kinase labeling system (Life Technologies, Rockville, MD). 1 µl of
radiolabeled probe (roughly 50,000 cpm) was mixed with 19 µl DNA binding reaction
mixture that contains 250 ng VDR, 250 ng RXR, 10 mM Tris-Cl (pH7.9), 100 mM KCl,
0.1 mM EDTA, 15% glycerol, 100 µg/ml poly(dI:dC), 0.1 µg/µl bovine serum albumin, 1
mM DTT and 10-7 M 1,25VD. The mixture was incubated at room temperature for 30
minutes. For competition experiments, VDR/RXR was pre- incubated with 2 µg antiRXRβ, anti-Flag M2 antibody or excess amount of cold probes on ice for 20 minutes
before the EMSA reaction. The reaction mixture was resolved in a 5% non-denaturing
polyarylamide gel and protein-oligo complexes were revealed by autoradiography.
Construction of luciferase reporter plasmids, deletion and site-directed
mutagenesis
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To construct GADDLuc, GADD45 genomic DNA fragment from +366 to +2926
was amplified by PCR using primers described in the Material. The forward primer
contains a MluI and the reverse primer a BglII site. The amplified PCR fragment was
cloned into the MluΙ and BglΙΙ sites of pGL3-promoter vector.
Luc1 was generated by digesting the GADDLuc with KpnΙ and religation. Luc2
was generated by digesting GADDLuc with MluΙ and EcoRΙ, filling with Klenow
fragments and religation. Luc3 was generated by sub-cloning into BglΙΙ site of pGL3promoter vector a 440 bp DNA fragment released from GADDLuc with BamHΙ and
BglΙΙ. Luc4 was generated by digesting GADDLuc with BglΙΙ and EcoRΙ, filling with
Klenow fragments and religation. Luc5 was generated by sub-cloning into pGL3promoter vector at KpnΙ and BglΙΙ sites a 777 bp fragment released from Luc2 with KpnΙ
and BamHΙ.
Site-directed mutagenesis was performed as described (Lee, 2002) using
QuikChange Site-directed Mutagenesis kit (Stratagene, La Jolla, CA). The sequence of
all mutant constructs was verified by DNA sequencing.
Transcriptional analysis
For trans fection studies, OVCAR3 cells were plated in 15% FBS RPMI 1640
medium at 1 × 105 cells/well and HeLa cells in 10% FBS DMEM at 5 × 104 cells/well in
12-well plates. On the next day, OVCAR3 cells were transfected by Lipofectamine Plus
and HeLa cells by Lipofectamine following the protocol from Invitrogen. 4 h posttransfection, cells were treated with 1,25VD or vehicle in fresh medium for 36 h. Cells
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were harvested and luciferase and β-galactosidase (β-gal) assays were performed as
described (Lee, 2000 and 2002).
Chromatin immunoprecipitation (ChIP) assays
For ChIP assays, OVCAR3 cells were treated with EOH or 10-7 M VD for 60 min
and cross- linked with 1% formaldehyde at room temperature for 10 min. Then, the cells
were incubated with 0.125 M glycine for 5 min, washed, scraped in ice-cold PBS
containing protease inhibitor cocktail (Roche) and lysed in buffer (pH 8.0) containing 5
mM PIPES, 85 mM KCl, 0.5 % NP 40 and protease inhibitor cocktail. Cell nuclei were
re-suspended in lysis buffer containing 50 mM Tris-Cl (pH. 8.1), 10 mM EDTA, 1% SDS
and protease inhibitor cocktail. Soluble chromatin was prepared by sonication and diluted
in buffer containing 16.7 mM Tris-Cl (pH 8.1), 0.01 % SDS, 1.1% Triton X 100, 1.2 mM
EDTA, 167 mM NaCl and protease inhibitor cocktail. The diluted chromatin solution was
pre-cleared with pre- immune serum and protein G agarose (Santa Cruz) pre-coated with
sheared sperm DNA (Ambion). Immunoprecipitations were carried for overnight at 4 o C
with rat anti-VDR antibody or Rat IgG (Sigma) followed by incubation with pre-coated
protein G agarose for 2 h at 4 o C. The beads were sequentially washed at room
temperature for two times (10 min/wash) in each of the following buffers: the dilution
buffer, TSE-500 wash buffer containing 20 mM Tris-Cl (pH 8.1), 0.1% SDS, 1% Triton
X 100, 2 mM EDTA, 500 mM NaCl) and LiCl/detergent wash buffer containing 100 mM
Tris-Cl (pH 8.1), 1% NP40, 1% deoxycholic acid, 500 mM LiCl). After the final wash in
TE buffer containing 10 mM Tris-Cl (pH 8.0) and 1 mM EDTA, the immunocomplexes
were eluted from the beads with 50 mM NaHCO3 and 1% SDS for two times. The
immunocomplexes were pooled and heated at 65 o C overnight to reverse the cross-
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linking. DNA was extracted from the immunocomplexes using a QIAquick Spin Kit
(Qiagen, CA). 2 µl out of 30 µl DNA extract was used for PCR.
Immunoblotting analysis
Immunoblotting analysis of GADD45 protein was performed as previously
described (Li, 2001) with modification. Briefly, cells were harvested in lysis buffer
containing 50 mM Tris-Cl (pH 7.5), 1% NP-40, 0.25% deoxycholic acid, 400 mM NaCl,
1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 1 mM Na3 VO4 , 1 mM NaF, and
protease inhibitor cocktail. The protein concentration of the cell lysate was assayed using
Bio-Rad kit. Extracts containing 50 µg of protein were separated on a sodium dodecyl
sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) and transferred to
nitrocellulose membrane. GADD45 was detected using ECL Kit following the
manufacture’s instruction (Amersham-Pharmacia Biotech, Piscataway, NJ). The
immunoblotting analysis of cdc2, cyclinB1 and VDR was performed similarly as for
GADD45 except that the cell extracts were prepared in buffer containing 20 mM Tris-Cl
(pH 7.5), 300 mM NaCl, 3 mM EDTA, 3 mM EGTA, 100 µM Na3 VO4 , 1% NP-40, and
protease inhibitor cocktail (Zhang, 2003).
Establishment of stable clones from OVCAR3 cells
OVCAR3 cells were transfected with 10 µg pCMVAS45 or hTERT plasmid
together with 0.5 µg pcDNA3 for the establishment of GADD45 anti-sense, telomerase
stable clones. pcDNA3 alone transfected into OVCAR3 cells for the Vector-OVCAR3
controls. For the establishment of stable clones with GADDLuc reporter, OVCAR3 cells
were transfected with 10 µg GADDLuc plasmid and 0.5 µg pcDNA3. All stable clones
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were obtained through selection with 100 µg/ml G418 for a period of about 4 weeks and
isolated by cloning with glass cylinders.
In vitro immunocomplex kinase assays
In vitro immunocomplex kinase assays were performed as described (Lee, 2000)
with minor modifications. In brief, cells were washed with ice-cold PBS and cellular
extracts are prepared in buffer containing 20 mM Tris-Cl (pH 7.5), 300 mM NaCl, 3 mM
EDTA, 3 mM EGTA, 100 µM Na3 VO4 , 1% NP-40, protease inhibitor cocktail. Cellular
extracts containing 200 µg protein were immunoprecipitated with anti-cyclin B1
antibody. Kinase assays were performed at 30 o C in 20 µl reaction buffer containing 20
mM HEPES (pH7.5), 5 mM MgCl2 , 2 mM EDTA, 2 mM EGTA, 1 mM dithiothreitol, 20
32

µM ATP, 3 µg histone H1, and 10 µCi [γ- P] ATP. Reactions were terminated by adding
2 × SDS-PAGE sample buffer, analyzed on a SDS-PAGE and visualized by
autoradiography.

Telomerase activity assay
Telomerase activity was measured with the telomerase PCR- enzyme-linked
immunosorbent assay (ELISA) kit (Roche) base on the telomeric repeat amplification
protocol (TRAP) assay. Cells were suspended in lysis buffer (Roche), incubated on ice
for 30 min, and then centrifuged at 14000 × g for 20 min. Supernatants were used for the
detection of telomerase or flash frozen and stored at -80 o C. According to the
manufacturer’s instructions, 200 ng of protein extract were assayed for telomerase
activity after 30 cycles of amplification by PCR. The resulting PCR product (5 ul) was
quantified by ELISA. Telomerase activity was expressed as absorbance values (OD)
measured using a microtiter reader at 450 nm with a reference wavelength of 595 nm. All
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assays were performed in duplicate and a dilution series of control telomerase extracts
was always examined in parallel to give titration curve for normalizing experimental
variations.
RT-PCR analysis
Analysis of the expression of hTERT and GAPDH were performed by reverse
transcription-PCR amplification as previously described (Nakamura, 1997). RNA was
isolated with Trizol (invitrogen) according to the manufacturer. 1 µg of total RNA was
reverse-transcribed using the RNA PCR kit version 2 (TaKaRa, Ohtsu, Japan) with oligodT primers. To amplify the cDNA, l aliquots of the reverse-transcribed cNNA (20ul)
from 2 µg of RNA were subjected to PCR in 25 ul of 1x buffer (10mM Tris-Cl (pH8.3),
1.5 mM MgCl2 , 50 mM KCl), containing 1 mM each of the dNTP; 1.25 U of Taq NDA
polymerase (TaKaRa); and 0.2 uM of specific primers. Primer sequence was chosen to
amplify a 145-bp region presenting in all transcripts of hTERT mRNA 1784 (5’cggaagagtgtctggagcaa- 3’) and 1910 (5’- ggatgaagcggagtctgga- 3’) for 30 cycles (94o C
for 30s, 60 o C for 30s, 72 o C for 90s). As a positive control, GPDH mRNA was amplified
in parallel using primers 5’-ctcagacaccatggggaaggtga- 3’ and 5’- atgatcttgaggctgttgtcata3’ for 16 cycles (94o C for 30s, 55 o C for 30s, 72 o C for 45s). PCR products were
electrophoresed in 15% polyacrylamide gel and stained with SYBR green. For semiquantification of hTERT mRNA expression, serially diluted cDNA reverse-transcribed
from 2 µg RNA (corresponding to 50 ng to 1 µg RNA) was subjected to RT-PCR.
Primers, probes for Real-time PCR
Primers and prodes for the hTERT gene were chosen with the assistance of the
Primer Express (Perkin-Elmer Applied Biosystems, Foster city, CA). To avoid
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amplification of contaminating genomic DNA, either upstream or downstream primer
was placed in a different exon. Forward primer of hTERT1 (1909F) and probe1 was
placed in exon 4, whereas reverse primer (2017R) was spanning exon 4 and 5 junction.
Forward primer of hTERT2 (3081F) was spanning exon 13 and 14 junction, probe2 and
reverse primer (3162R) in exon 14. The nucleotide sequences are as follows:
hTERT1: 1909F: 5’- gtccagactccgcttcataa-3’; 2017R: 5’-gagacgctcggccctctt-3’;
FAM/TAMRAprobe1: 5’-ttctggctcccacgacgtagtccatg-3’; PCR product size: 109bp.
hTERT2: 3081F: 5’-cgtacaggtttcacgcatgtg-3’; 3162R: 5’-atgacgcgcaggaaaaatg-3’;
TAM/TAMRAprobe2: 5’-agctcccatttcatcagcaagtttggaag-3’. PCR product size: 82bp.
Real-time PCR
RNA was prepared using the RNasy RNA isolation kit (Qiagen) and DNase
digested on-column using RNase- free DNase set (Qiagen) and then reverse-transcribed.
An RNA pool was generated by mixing aliquots of RNA from cells treated with vehicle
or 1,25VD for various times. Concentrations of the pooled RNA ranging from 0 (buffer
alone) to 50 ng/µl were used in the PCR analysis to generate the standard curve for each
gene. The Ct value was generated by the ABI PRISM 7700 SDS software version 1.7 and
then exported to an Excel spreadsheet where equations from the standard curve were
generated. Using the Ct values, concentrations of the hTERT and GAPDH mRNAs were
calculated from the equations. Each sample was analyzed at two different concentrations
(50 ng/µl and 2 ng/µl) with only results in the most sensitive region of the standard curve
presented. Samples at each concentration were analyzed in triplicates. hTERT levels were
normalized to the corresponding input total RNA, base on quantitation of GAPDH.
Telomere length analysis
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Telomere length was measured using a non-radioactive chemiluminescent assay
developed by Roche Diagnostics. In brief, genomic DNA was isolated using a Roche
DNA isolation kit. 5 µg DNA was digested overnight with 20 U of Hinf I and Rsa I,
fractionalized on a 0.8% agarose gel. Gels were denatured for 30 min and then
neutratlized for 30 min. DNA was transfered to a nylon membrane, hybridized with
digoxigenin 3’- end tailing – labeled (Roche) (TTAGGG)4 oligonucleotides overnight at
50 o C in PerfectHyb solution (Sigma). Membranes were washed twice in 2 x SSC, 0.1%
SDS for 15 min at RT and twice in 0.1 x SSC, 0.1% SDS for 15 min at 50 o C. The probe
was detected by the digoxigenin luminescence detection and processed by Southern
blotting and chemiluminescent detection. The average telomere length can be determined
by comparing the signals relative to a molecular weight standard.
Immuno histochemical analysis
To confirm the VDR and RXR expression in normal human tissue, paraffinembedded tissues were immunostained with anti- VDR antibody and anti-RXR antibody.
The signal was detected with the avidin-biotin complex (ABC) immunoperoxidase kit
(Vectastatin Elite ABC, Vector Laboratories, CA). The cell nucleus was counterstained
with hematoxylin. Positive (skin tissue) and negative controls (pre-immune serum) were
included in all immuno-reactions.
Nude mouse tumor studies
The studies were performed as described (Blutt, 2000) with little modification.
Briefly, OVCAR3 cells were trypsinized and resuspended in 50% Matrigel Matrix
(Becton Dickinson, San Jose, CA) at a concentration of 2x106 cells/100ul matrix. Female
athymic nude mice, ~6 weeks of age, on a vitamin D-deficient diet supplemented with
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1% calcium, received injections s.c. with 2x106 cells on the dorsal surface. After tumors
grow to a volume of about 150mm3 , the mice were randomly divided to three groups
treated with placebo or EB1089 at 0.3 or 1.0µg/kg/day. EB1089 was delivered daily by
gavage. The size of the tumor was determined by measuring the tumor diameters with a
Vernier caliper every 5 days and using the formula tumor volume=dxDxD/2 (where d and
D represent the shortest and the longest diameter, respectively).
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